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Abstract 
Buprenorphine is a widely used analgesic. Its in vivo properties are partial agonism at 
11 receptors and antagonism at K receptors. For the investigation of the role of the 
tertiary alcohol function in the pharmacology of buprenorphine, a series of ring 
constrained analogues of buprenorphine, in which the tertiary hydroxyl substituent on 
Ct9 is fixed in different positions either above (BU46 and BU9S) or below (BU47, 
BU96, BU 48 and BU 61) the plane of the ring, have been studied in several biological 
test systems, include binding assays, isolated tissue bioassays and intracellular assays. 
In binding assays, all the buprenorphine analogues tested showed similar high affinity 
(nanomolar) for 11, a and K opioid receptors in mouse brain homogenates and !.I. 
receptors in SH-SY5Y human neuroblastoma cells. This is consistent with the values 
obtained for buprenorphine. The results demonstrate that the position of the tertiary 
alcohol function does not play an important role in controlling receptor-binding 
affinity. 
In the mouse vas deferens preparation, all compounds showed full agonist activity with 
the ICso values in the low nanomolar range (0.2nM-7.2nM) and no obvious difference 
in efficacy and potency between the isomeric pairs (e.g. ICso values for the isomeric 
pair BU46 and BU47 were 1.3nM and 3.6nM respectively). Antagonism by the 1) 
selective ligand nalttindole indicated that all compounds exerted their effects via 1) 
receptors. However, the least strained ring derivative BU48, in which the position of 
the OH is constrained in a 6·membered ring, was the most potent compound with an 
ICso value being 10-30 times lower than that of other compounds tested. Hence the 
position of the OH may affect the efficacy and potency at 1) receptors, although the 
higher potency of BU48 may relate to the 6-membered ring itself, rather than the 
slightly different position of the OH function. 
In the guinea-pig ileum preparation, all compounds acted as potent and full agonists. 
For most of compounds ICso values were in the range 1.4nM-3.7nM. However, 
compound BU46 (ICso O.3nM) was more potent by 5-\0 fold than the other 
compounds. The K selective antagonist nor-BNI prevented the agonist action affording 
Ke values in line with K-mediated responses. The isomers BU46 and BU47 showed a 
10-fold different in potency, which suggests that the position of tertiary OH function 
has a influence in the determination of efficacy and potency at K sites. However, this 
was not the case for the isomeric pair BU95 and BU96. These compounds contain two 
extra methyl substituents which could mask the effects of the OH function. 
The efficacy of the compounds at 11 opioid receptors was determined as the ability to 
stimulate eSS1-GTP'yS binding in SH-SY5Y cell membranes. All compounds were 
agonists with slightly lower efficacy than buprenorphine which itself gave 70% of the 
response seen with the full agonist DAMGO. The ECso values matched the affinity of 
the compounds for the J.l. opioid receptors under similar buffer conditions. The partial 
agonist profile of some of the buprenorphine analogues was also confirmed by the 
cyclic AMP assays. It is concluded that the position of tertiary OH function does not 
alter the potency and efficacy of the compounds at 11 opioid receptors. 
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numbered 17 so that the C7 a; side chain starts with C20 and not C19 as used 
throughout this thesis. Thus C20 becomes C21 • 
CHAPTER 1 INTRODUCTION 
1.1 Opioid receptors and their ligands 
Morphine (Figure 1.1) has been used for many centuries to relieve pain. However, 
very little progress was made to answer the question of how morphine was able to 
elicit pain relief, or its myriad of other pharmacological effects, until the early 1970's. 
Figure 1.1 Morphine 
In 1973 several groups, working independently, published results demonstrating that 
opiates bind to stereospecific receptors in central nervous system tissues [Pert & 
Snyder, 1973; Simon et al., 1973; Wong & Hong, 1973]. These findings initiated the 
search for endogenous opioid ligands. Two years later Hughes et al. [1975] isolated 
and characterised two pentapeptides, later named [Met5]-and [Leu5]-enkephalin 
(Figure 1.2), from porcine brain. These peptides mimicked the action of morphine in 
in vitro pharmacological assays, in particular using electrically stimulated smooth 
muscle preparations. Subsequently the larger peptide l3-endorphin (Figure 1.2) 
containing the [Mets]-enkephalin sequence at its N-terminus [Bradbury et al., 1976] 
1 
and the dynorphins (Figure 1.2) containing [Leus]-enkephalin at their N-terrninus 
[Goldstein et al., 1975] were discovered and extensively investigated. 
(a) Tyr-Gly-Gly-Phe-Met (b) Tyr-Gly-Gly-Phe-Leu 
(c) Tyr-Gly-GlY-Phe-Met-Thr-Ser-Glu-Lys-Ser-Glu-Thr-Pro-Leu-Val-
Thr-Leu-Phe-Lys-Asn-Ala-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln 
(d) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-GIn 
Figure 1.2 (a) [Mets]-enkephalin, (b) [Leus]-enkephalin, (c) ~-endorphin and 
(d) dynorphin 17 
It is now generally accepted that there are three types of opioid receptor through 
which the physiological functions of opioids are mediated. The concept of multiple 
opioid receptors was fIrst postulated by Martin et al. [1976] following behavioural and 
neurophysiological experiments in the chronic spinal dog. These authors suggested 
that there were at least three types of opioid receptor which they termed 11, K and a. 
Morphine was classified as a typicall1-agonist and ketocyclawcine was proposed as a 
K-agonist, while N-allylnormetawcine (SKFI0,047) was purported to act as an 
agonist at a-receptors. Many of the effects of a-agonists, however, are not reversed by 
the opioid antagonist naloxone, and it is now commonly accepted that a-sites are not 
opioid receptors. Experiments using isolated tissue preparations and receptor ligand 
binding studies supported the concept of opioid receptor heterogeneity. The 
observation that the rank order of potency of morphine and the enkephalins was not 
the same in the guinea-pig ileum and the mouse vas deferens preparations, and the 
2 
~------------------------------------------------------------------
drugs were differentially sensitive to the opioid antagonist naloxone in the two 
preparations, led to the discovery of the I) receptor. Thus, three types of opioid 
receptor 1.1, I) and lC are now recognised [Lord et aI., 1977]. There is also some 
evidence that subtypes of opioid receptors may exist, although this is still controversial 
[fraynor, 1994]. 
A number of studies have examined the opioid receptor selectivity of endogenous 
opioid peptides. The endogenous ligands with some selectivity for &-receptors are 
[Leus]-and [Md]-enkephalin, although these compounds also act at l.1-receptors 
[Lord et al., 1977]. ~-Endorphin acts at both J-t- and I) receptors with equal affinity 
[Lord et al., 1977]. The dynorphins act preferentially at lC-receptors [Goldstein et 
al.,1981]. 
Synthetic compounds acting selectively at the three types of opioid receptor with a 
higher degree of stability to metabolism than the endogenous ligands have been 
developed. Widely used Il-agonists include morphine itself and the synthetic pepide 
DAMGO ([D-Ala2, MePhe\ Gly-ols]enkephalin) [Handa et aI., 1981], the latter being 
the most selective J-t-agonist currently available with very low affInity for &-and lC-
receptors [Kosterlitz & Paterson, 1981]. Commonly used I) agonists include DADLE 
([D-Ala2, D-Leus]enkephalin) [Magnan et al., 1982], DSLET([D-Se?, Leus, 
Thr'1enkephalin) [Gracel et al., 1980] and DPDPE ([D-Pen2, D-Pen5]enkephalin) 
[Mosberg et al., 1983]. The latter is highly selective and therefore usually used to 
label the &-receptor binding site and examine &-receptor mediated functions. Selective 
lC-agonists include U69,593 [Lahti et al., 1985] and CI977 [Hunter et aI., 1990] 
(Figure 1.3). 
Agents acting as antagonists have also been synthesised.Most studies have employed 
the opioid antagonists naloxone and naltrexone, which unfortunately do not clearly 
3 
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discriminate between different types of opioid receptor. More recently, the selective ~­
antagonist cyprodime [Schmidhammer et al., 1989), K-antagonist norbinaltorphimine 
(nor-BNl) [portoghese et al., 1987] and O-antagonist naltrindole (NTI) [Portoghese et 
al., 1988] have been synthesised and these provide useful tools for further 
characterising receptors and screening new opioid ligands (Figure 1.4). 
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1.2 Molecular biology of the opioid receptors 
~-, &- and lC- Opioid receptors have been extensively studied in various tissues and 
cell lines. However, the lack of highly selective ligands, in particular labelled 
antagonists for each receptor type, combined with the lack of animal tissues which 
express a single type of opioid receptor, has hindered further characterisation. 
Recently, several groups have reported the molecular cloning of the 0, ~ and lC 
receptors [Kieffer et a1. 1992; Evans et al.,1992; Chen et al. 1993; Yasuda et al. 1993]. 
The availability of the cloned individual receptor types should allow for the 
identification of the structural features of ligand-receptor interactions. 
The mouse <5 receptor contains 372 amino acids and was cloned using a strategy 
which involved extraction of cDNA from neuroblastoma x glioma NGIOS-15 hybrid 
cells, which contain a high density of <5 receptors [Chang & Cuatrecasas, 1979]. The 
pharmacological profJ1e of the cloned receptor in subsequently transfected cells 
confmned that it was a 0 receptor. In addition, the cloned receptor showed the ability 
to mediate agonist inhibition of cyclic AMP formation, which indicated that the 
receptors were functionally coupled to adenylyl cyclase. Subsequently, molecular 
cloning and functional expression of a IJ.-opioid receptor from rat brain and a lC-opioid 
receptor from mouse brain was achieved. The ~- and lC-opioid receptors consist of 
398 and 380 amino acids respectively. More recently the amino acid sequences of the 
human J.L and " opioid receptors have been published [Wang et al.,1994; Knapp et al., 
1994]. The amino acid sequences of the tbree opioid receptor types are given in Figure 
1.5. 
All three types of opioid receptor belong to the superfamily of seven transmembrane 
domain G-protein coupled receptors. Thus their general structure is of an extracellular 
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amino terminus, 7 transmembrane regions, 3 extracelluar loops, 3 intracellular loops 
and an intracellular carboxyllerminus, as outlined in the diagram (Figure 1.6). 
Consideration of the amino acid sequences of the opioid receptors shows that 57% of 
the amino acid sequences of the three types of opioid receptors are identical. Much 
homology is seen in transmembrane domains 2(84%» 3(82%) > 5=7(71%) > 6(50%) 
> 1(45%) > 4(30%). The sequences of the intracellular loops are also highly 
conserved; loop I shows 90%, loop III shows 91% and loop V shows 78% sequence 
homology respectively, whereas the extracellular loops are generally much more 
divergent; loop II shows 67% loop IV shows 24% and loop VI shows 7% sequence 
homology. There is very little sequence or size homology at either the amino or 
carboxyl termini. The divergent extracellular regions of the receptors may prove to be 
vital for ligand binding and therefore explain ligand selectivity profIles. 
Knowledge of the amino acid sequence and therefore the structure of the opioid 
receptors should lead to a better understanding of their function. Several groups are 
currently investigating chimeric receptors [Meng et aI., 1994; Xue et al .• 1994J. in 
which, for example. a sequence from the Jl receptor replaces a specific sequence in the 
le receptor. The binding and function of this chimeric receptor is then compared to the 
original receptor to elucidate which regions of the receptor may be responsible for 
determining ligand specificity. Alternatively the effects of mutagenesis or deletion of 
certain amino acids can be tested [Hong et al., 1994J. In the long-term these kinds of 
studies should provide information useful for the rational design of opioids. 
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1.3 Receptor.Effector Coupling 
1.3.1 G proteins 
The interaction of agonist with specific receptors at the cell surface represents only the 
first step in a cascade of molecular events that underlies transmembrane signalling. 
Stimulation of these receptors results in activation of effector proteins such as 
enzymes or ion channels, which synthesise or mobilise chemical 'second messengers' 
that initiate characteristic actions within the cell. In many cases, a group of proteins, 
known as G proteins play an essential transducing role in linking cell-surface receptors 
to effector proteins at the plasma membrane. 
G proteins are heterotrimers, composed of three distinct subunits: a:, P and r. The Pr-
subunit exists as a tightly associated complex that functions as a unit. The a:-subunit 
has a single, high affInity binding site for guanine nucleotides. The a:-subunits clearly 
differ between members of the G protein family while the Pr units appear to be shared 
among some a:-subunits to form specific oligomers [Gilman, 1986]. At present, G 
proteins are classified on the basis of their amino acid sequences into major families, 
namely G., G .. Gq Gq and G12 [Hepler & Gilman, 1992]. The G proteins differ in their 
effects on regulation of intracellular effector systems. 
G proteins act as switches turning the transmembrane signal on and off. They are able 
to achieve this function by a cycle of events known as the G protein turnover cycle 
(Figure 1.7). In the resting state, a receptor is unoccupied by ligand and likely to be 
unassociated with other components of the pathway. The G protein exists as an 
unattached uPr trimer, with GDP (guanine diphosphate) occupying the nucleotide site 
on the u-subunit. When a receptor is occupied by an agonist molecule, a 
conformational change occurs, presumably involving the cytoplasmic domain of the 
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receptor, causing it to interact with aPr. Association of aPr with the receptor causes 
the bound GDP to dissociate and to be replaced with GTP (guanine triphosphate), 
which in turn causes dissociation of a-GTP from the ~r subunits. Both the GTP bound 
a subunit and /3r can associate with various enzymes and ion channels, causing 
activation or inactivation of downstream events. The process is terminated when the 
hydrolysis of GTP to GDP occurs through the intrinsic GTPase activity of the Cr.-
subunit. The resulting a-GDP dissociates from the effector and reassociates with /3r, 
completing the cycle. This mechanisms results in amplification of the signal because a 
single agonist-receptor complex can activate several G-protein molecules, and each of 
these in turn can associate with an effector enzyme for long enough to produce many 
molecules of second messenger. 
The a subunits of the various G proteins differ in structure. In some cases, a subunits 
possess specific residues that can be covalently modified by bacterial toxins. Cholera 
toxin catalyses the transfer of the ADP-ribose moiety of NAD (nicotinamide adenine 
dinucleotide) to a specific Arg residue in the G, protein a subunit. Similarly, pertussis 
toxin ADP-ribosylates Gi a subunits that possess a specific Cys residues near the 
carboxyl terminus. Therefore modification of a-subunits by cholera toxin causes 
constitutive activation inhibiting GTPase activity and lengthening the life time of active 
a-GTP, whereas modification by pertussis toxin prevents receptor-mediated activation 
of G proteins [Hepler & Gilman,1992]. Not all G protein are toxin-sensitive, for 
example, G proteins insensitive to either of these toxins are thought to regulate 
receptor-mediated activation of phospholipase C (either Gq and lor G I2). 
1.3.2 Effector systems 
G protein coupled effector systems include many membrane enzymes, such as adenylyl 
cyclase, guanylyl cyclase, phospholipase C and phospholipase A2 . as well as a variety 
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of ion channels [Strader et al., 1994]. Opioid receptors have been shown to couple to 
adenylyl cyclase, phospholipase C, and K+ and ci+ ion channels. 
Adenylyl cyclase Cyclic-AMP(cAMP) is a nucleotide synthesised from A1P by the 
action of the enzyme adenylyl cyclase and hydrolysed to S'-AMP by the action of 
phosphodiesterase enzymes. Many different drugs, hormones and neurotransmitters 
produce their effects through 0 proteins by increasing or decreasing the catalytic 
activity of adenylyl cyclase and thus changing the intracelluar concentration of cAMP. 
cAMP has a regulatory action on many intracellular functions, including, for example, 
energy metabolism, cell division and cell differentiation in addition to ion channel 
function and ion transport, leading to changes in neuronal excitability and in 
contractile proteins in smooth muscle. These varied effects are caused through the 
common mechanism of activation of various protein kinases by cAMP. These enzymes 
catalyse protein phosphorylation and thereby regulate the function of target proteins. 
Opioid receptors have been shown to be negatively coupled to adenylyl cyclase via Gi 
and 0 0 proteins [North et al.,1987]. A direct influence of opioids on intracellular levels 
of cAMP was first shown in the 0 receptor containing NO 108-1S cells, in which the 
cAMP forming enzyme, adenylyl cyclase, was inhibited by the binding of opioids to 
cell surface receptors [Klee & Hvrenaberg, 1976]. Furthermore, activation of Jl and K 
opioid receptors results in inhibition of cAMP formation as demonstrated for example, 
in SH-SYSY cells and guinea-pig brain [Sadee, et al. 1988; Lambert et al. 1993;]. The 
ability of opioids to inhibit adenylyl cyclase has been widely used as a measure of 
opioid agonist activity. 
Phospholipase C Many hormones and neurotransmitters can activate 
phosphoinositide-speciflc phospholipase C, an effector enzyme that catalyses 
hydrolysis of the minor lipid phosphatidylinositol 4,S- biphosphate to form two second 
messengers, inositol 1,4,S-triphosphate (IP3) and diacylglycerol. 1bis receptor-
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mediated activation of phospholiphase C involves functional G proteins [Heper & 
Gilman,1992J. IP3 acts very effectively to release calcium from intracellular stores, by 
binding to a receptor on the membrane of the endoplasmic reticulum. The action of 
calcium depends on its ability to regulate the function of various enzymes, contractile 
proteins and ion channels. Diacylglycerol also acts as a second messenger since it 
directly changes the activity of membrane-bound protein kinase C, and thus controls 
protein phosphorylation. 
Evidence for the coupling of opioid receptors to phospholipase C and the generation 
ofIP3 is controversial [Yu & Sadee, 1986; Barg et al., 1992J. but growing [Okajima et 
al., 1993; Chen & Huang 1991J. Recently. Il-Opioid receptor mediated activation of 
phospholiphase C via a pertussis toxin-sensitive G protein has been successfully 
demonstrated in human neuroblastoma SH-SY5Y cells [Smart et al., 1994J. 
Regulation of ion channels G protein coupled receptors can interact with Ca * and 
re' ion channels. There is good evidence in support of G protein involvement [North et 
al., 1987J. The Il selective ligand DAMGO and 8 selective ligand DPDPE are capable 
of increasing the conductance of the inwardly rectifying potassium channels and thus 
lead to membrane hyperpolarization. Furthermore. K and IJ. receptors are linked to 
voltage dependent Ca ++ channels and the activation of !( and I! receptors leads to a 
decrease of Ca* entry. Thus, it has been suggested that opioid receptor activation 
results in the regUlation of cation conductance via G proteins, which in turn induces 
membrane hyperpolarization and this leads to a reduction in neurotransmitter release. 
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lA Theoretical consideration in receptor-Iigand interactions 
The agonist activity of an opiate or opioid depends upon the principles of affinity and 
efficacy. 
Affinity is the ability of a drug to bind to its receptor, which is defmed as the 
reciprocal of the equilibrium dissociation constant of the drug for the receptor. 
Efficacy is a parameter that varies between different drugs and expresses the ability of 
the drug-receptor complex to elicit a physiological response. Full agonists which can 
produce maximal effects, have high efficacy; for a pure antagonist efficacy is zero; 
agonists which can produce only submaximal effects have intermediate efficacy, and 
are termed partial agonists. The concept of efficacy was originally defmed by 
Stephenson [1956]. 
In the 'occupation' theory of drug-receptor interaction, it is assumed that the 
magnitude of the biological response is linearly proportional to fractional receptor 
occupancy such that 
ED [RD] 
-=--
EM [RI] (1) 
where ED the observed response, EM is the maximal response possible, [RD] is the 
concentration of drug-receptor complex, and [Rt] is the total concentration of 
receptors. Assuming a simple bimolecular interaction, the binding of the drug to its 
receptor may be described by the law of Mass Action, such that 
[RD] [D] 
[Rt] = [D] + KD (2) 
where [D] is the concentration of drug. 
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Later modifications of receptor theory recogonised that a nonlinear relationship exists 
between receptor occupation and tissue response [Stephenson,· 1956]. Stephenson 
suggested that the measured response is some function of the stimulus (S) which is 
generated by interaction ofligand and receptor. Thus 
ED (e[RD]) (e[D] ) 
EM =/(S)==/ [Rtf ==/ [D]+KD (3) 
where e is efficacy, the parameter that relates stimulus to occupancy, and f represents 
the transducer function which describes the characteristics of the responding system. 
The concept of receptor reserve (or spare receptors) is implicit in this model, since an 
agonist with a high efficacy value needs to occupy only a fraction of the total receptor 
population to elicit a maximal response. Thus, the concentration which produces a 
50% maximal response is less than the concentration which is necessary to occupy 
50% of total receptor pool. 
Furchgott [1966] has argued that efficacy (e), as defmed in equation (3) is a drug and 
tissue· dependent term, which reflects both the ability of the agonist to induce an 
active receptor-effector complex and the total number of receptors in the system, i.e. 
e =E [Rt] (4) 
where E is 'intrinsic efficacy', a strictly drug-related property, and [Rt] is the total 
concentration of receptors. Intrinsic efficacy (E) should be constant for a given drug-
receptor pair across species and tissues [Kenakin, 1983], whereas efficacy (e) varies 
with receptor density. Therefore, agonist activity is dependent upon factors which are 
specific to the drug (KD, drug dissociation constant, and E intrinsic efficacy) as well as 
upon factors which are specific to the target tissue (f, the function relating stimulus to 
response, and [Rt] total receptor concentration). When receptor density is high, the 
value e will be high, and the agonist may produce a maximal response by occupying a 
small proportion of the total receptor population (Le., EDso L KD). Where receptor 
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density is low, the value of e will be low, and the same agonist may occupy the total 
receptor population without producing a maximal response i.e., behave as a partial 
agonist 
Another widely used concept is 'intrinsic activity', which describes the ability of the 
drug-receptor complex to elicit the observed phannacological response. This was 
defined by Ariens [1954] as: 
E=ex [DR] (5) 
where E is observed response, ex is intrinsic activity, and [DR] is the concentration of 
drug-receptor complex. 
This defInition is strictly based on the assumption of occupation theory, i.e. the linear 
relationship between receptor occupation and tissue response. So the magnitude of 
intrinsic activity is equal to the magnitude of the maximal response. Thus a partial 
agonist producing a maximal response that was 40% of the tissue maximal response 
has ex = 0.4. The measurement of intrinsic activity is a widely used method for 
quantifying the ability of a drug to produce a response. However, caution should be 
used since that this parameter is also drug and tissue dependent and cannot be used to 
classify drugs without awareness of the tissue factors. In reality the observed 
pharmacological response is not a linear function of receptor occupancy, therefore, 
quantifIcation of agonism by intrinsic activity depends on the recognition of the 
effIciency of stimulus-response coupling. 
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1.5 The oripavines: a family of alkaloid derivatives containing highly 
potent analgesics 
Chemical modification of opioid analgesics have been caried out for many years to 
design compounds that have greater pain-killing capacity and less side-effects than 
morphine. Much of this work has been based on the naturally occurring alkaloids. 
Thebaine is one of the components of the opium poppy and serves as the starting point 
in the synthesis of the thevinols and orvinols series of agonists and antagonists (Figure 
1.9). 
Bentley and coworkers prepared many derivatives of thebaine using the Diels-Alder 
reaction. The idea for synthesising this series of compounds stemmed from the 
hypothesis that if morphine and related compounds bound to a receptor in order to 
initiate their response, molecular flexibility would permit a molecule to fit a number of 
different receptor types. This would lead not only to the required analgesic effects, but 
also a number of undesirable side-effects. Therefore it was thought that greater 
molecular rigidity would restrict receptor fit and afford a greater degree of selectivity 
towards the opioid receptor. Although such a view is probably an oversimplification, 
and devised before our knowledge of opioid receptor types, useful compounds 
resulted from this approach. In particular etorphine (Figure 1.8) was found, in animal 
studies, to be 2000-10,000 times more potent than morphine, depending on the test. It 
has been used in veterinary practice and in the immobilisation and capture of wild 
animals. Antagonists were also discovered in this series of compounds, such as 
diprenorphine (Figure 1.8) which is about 100 times more potent than nalorphine as a 
morphine antagonist in the mouse writing test [Blane, 1967]. Subsequently, the mixed 
agonist and antagonist buprenorphine (Figure 1.8) was synthesised, which is 75 times 
more potent than morphine as an agonist and 4 times more potent than nalorphine as 
an antagonist in rodents [Lewis, 1985]. 
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Many chemical modifications have been made in the exploration of the structure-
activity relationships of the thebaine Diels-Alder products (Figure 1.9) [!.ewis et, al., 
1973; Casy & Parfitt 1986]. Some of these are sumarised below: 
A ring modifications These have not been extensively studied, but in general 
additional aromatic substituents tend to reduce potency below that of the parent 
orvinols (which contain 3-0H) or thevinols (which contain 3-0Me). Compounds 
lacking an oxygen function at C-3lie between orvinols and thevinols in potency. 
D ring modifications Variation of the N-substituent are most often entailed. In this 
series the pattern of activity is much the same as that in other rigid opioids. Groups 
such as n-propyl, allyl, dimethylallyl, and cyclopropylmethyl afford antagonists in the 
thevinol series. However, with orvinols, the type of phannacological response elicited 
depends heavily upon the nature of Coring substitution in addition to the N-substituent 
C ring variations These have the most significant influence on pharmacological 
responses in this series. Originally the high potency of these compounds was thought 
to be due to the C-19 OH, which could undergo hydrogen-bonding interaction with 
the receptor protein. However, it was discovered that extremely high potency 
analgesics could exist in the oripavine series without a C-19 OH. Lipophilic 
substituents at C-19, preferably with a C-19 OH of appropriate geometry, gives some 
orvinols and thevinols a high level of opioid agonist activity, with potency greatly 
influenced by the size of the C-7 substituent [Casy and Parfitt, 1986]. 
Isomers with the R configuration at C-19 are more potent than the corresponding S 
isomers. For example, etorphine (19R) has 1000 times the agonist potency of 
morphine, whereas its diastereoisomer, although still with antinociceptive activity, is 
only 20 times potent than morphine. This was suggested to result from intramolecular 
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hydrogen bonding between the C-19 OH and the C-6 methoxy oxygen atom in the R 
isomer, which would direct the C-19 lipophilic group towards its receptor site [Lewis 
et, aI., 1971; Loew & Berkowitz, 1979]. However, with the 6-deoxy analogue a 
similar difference in analgesic activity between the diastereoisomers, has been found 
[Hutchins, 1981]. This indicates that intramolecular hydrogen bonding does not play a 
significant role in establishing the conformational preference for any R 
diastereoisomer-lipophilic site interaction. However, Hutchins and Rapoport [1984] 
examined 19-deoxy- and 6,20-epoxy orvinols and thevinols in which the high level of 
activity of some R isomers could also be explained by intermolecular H-bonding. 
To account for these various observations, Hutchins and Rapoport [1984] proposed 
two binding sites for the Coring, one for the C-7 lipophilic side chain located below C-
8 and approaching the 6,14-etheno bridge, and another, a hydrophilic receptor site to 
receive the C-19 hydroxy above the Coring. Some compounds in the series could 
interact with both sites, and others would only present a lipophilic interaction. Thus, 
the sites proposed would engage in synergistic and competitive binding of ligands, the 
response elicited being commensurate with a fit to one, or both, of the sites (Figure 
1.10). 
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subsites (adapted from Hutchins & Rapoport, 1984). 
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1.6 Pharmacological effects of buprenorphine 
The oripavine derivative buprenorphine has been widely used in the clinic as a 
analgesic for many years, particularly in the treatment of postoperative and cancer pain 
[Jasinski, 1979]. Because of its lower physical dependence liability, it is being 
evaluated for use in morphine dependent subjects in the treatment of addiction [Cowan 
& Lewis, 1995]. 
In vivo, buprenorphine (Figure 1.8) produces similar effects to morphine with a lower 
ceiling due to its partial agonist activity at II receptors [Cowan et aI., 1977]. However, 
in in vitro binding assays buprenorphine has high affinity at ll, /) and 1C opioid binding 
sites [ViIliger, 1984]. 
The main features of the pharmacology of buprenorphine are its potent analgesic 
activity with long duration of action and low physical dependence liability [Jasinski, 
1979]. In vitro studies [Ranee & Dickens, 1978; Manara, et aI., 1978] have 
demonstrated that buprenorphine has extremely slow kinetics, which could explain its 
slow onset and long duration of the action. The rate at which a drug leaves its receptor 
sites on challenge with an antagonist or on abrupt withdrawal of the opioid seems to 
be of importance in detemlining the severity of the abstinence syndrome produced. 
Buprenorphine dissociates extremely slowly from the receptor and this could balance 
the disturbance of homeostasis which results from abrupt withdrawal and therefore 
produce only a mild abstinence syndrome [Sharma, et aI., 1975]. 
In animal tests, a bell-shaped does-response curve for buprenorphine has been 
observed [Cowan et aI., 1977]. Thus as the concentration of buprenorphine is 
increased the observed agonist action is reversed. This could be explained by 
postulating an action of buprenorphine at two different opioid receptor systems with 
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different characteristics, i.e. buprenorphine interacts with one type of receptor to 
produce an agonist activity, whereas it interacts with a second type of receptor to 
produce an antagonist effect. This is referred to as non-competitive auto-inhibition 
[Ariens et al., 1964]. However, this idea has not been properly examined at the 
biochemical level. 
24 
,------------------------------------------------------------------------ -
1.7 Aims of the project 
As discussed earlier, the sterochemistry at C-19 in buprenorphine and related 
oripavines, which controls the position of the t-Butyl group and the tertiary OH, is 
important in determining the pharmacological profile of the compounds. In order to 
investigate the role of the tertiary alcohol function at C-19, a series of buprenorphine 
analogues in which the position of the alcohol function is fixed by incorporation into a 
ring structure have been synthesised by J.W.Lewis and colleagues at the University of 
Bristol. 
The aims of this study were to examine the affinity and efficacy of such 
conformationaly constrained analogues in several biological test systems. This should 
allow determination of the importance of the position of the tertiary alcohol function 
in this series of compounds, and thus help to point out important features, both in the 
molecule and in the binding pocket of opioid receptors, which control affinity and 
efficacy. 
Compounds examined are given in the Figure I. I I. These include the isomeric pairs 
BU46 & BU47 and BU95 & BU96 in which the OH is held in a 5-membered ring 
structure. In addition BU95 and BU96 contain methyl substituents, similar to 
buprenorphine. Two further compounds BU48 in which the OH is fixed in a 6-
membered ring and BU61 with same stereochemistry as BU47 but with introduction of 
a methyl group were also examined. For comparison a compound BU4 with the N-Me 
group was evaluated. 
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CHAPTER 2.0 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Radiochemicals 
eH]-DAMGO ([D-Alr, MePhe4, Gly(oli] enkephalin) (2.22TBqJmmol; 
6OCi/mmol), was from Amersham International plc., Alyesbury. 
eH]-DPDPE ([D-Pen2,D-Pens] enkephalin)(1.5TBqJmmol; 40.7Ci/mmol) 
was from Dupont NEN Research Products, Stevenage. 
eH]-CI977 (5R-(5a,7a,8~)-N-methyl-N-[7-(1-pyrrolidinyl)-1-
oxaspiro[ 4.5]dec-8-yl]-4-benzofuranacetamide) (0.78TBqJmmol; 
21.1Ci/mmol), was a gift from Dr.J.C.Hunter, Parke Davis 
Neuroscience Research Centre, Cambridge. 
eH]-Diprenorphine (1.1TBqJmmol; 30Ci/mmol) was bought from 
Amersharn International plc., Aylesbury. 
eH]-cAMP (3' S - cyclic adenosine monophosphate) (TBqJmmol; 
Ci/mmol) was from Dupont, NEN Research Products, Stevenage. 
eSS]-GTPyS (Guanosine5' -[y-thio] triphosphate) (46.1 TBqJmmol; 
1245Ci/mmol) was purchased from Dupont, NEN Research 
Products, Stevenage. 
Structures of the radiochemicals are given in Figure 2.1 
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[3,5,3HJTyr-D-Ala-Gly-MePhe-NH(CH2)2-0H (a) 
I I Cb) 
.. [3,5,3HJTyr-NH-CH(C(CH3)28)-CO-Gly-Phe-NH-CH(C(CH3)28)-C02H 
HO 
CH30 , 
, 
HOiCH3 
(c) 
CH3 
358 0 0 
11 11 11 
HO--P-O-P-O-P-O 
I I I o 
OH OH OH 
OH OH 
(e) (t') 
Figure 2.1 (a) CHJDAMGO, (b) CH]DPDPE, (c) CH]CI977, (d) CH)diprenorphine, 
(e) CHJcAMP and (t) eSS]GTPyS. 
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(d) 
2.1.2 Chemicals 
HEPES (N-[2-hydroxyethy l]piperazine-N' -[2-ethanesulfonic acid]), 
Trizma base (fris-(hydroxy-methyl]aminomethane), bovine serum 
albumin, Folin'sreagent, adenosine triphosphate (ATP), adenosine diphosphate 
(ADP), guanosine 5' -[y-thio]triphosphate (GTPyS) and norit activated charcoal were 
purchased from Sigma, Poole. 
CaC!z'2H20, ethylenediaminetetraacetic acid (EDTA),Glucose, KCI, KH~04' 
MgS04'7H20, NaCI, NaHC03, NaOH, NaC03, Na2HP04, CUS04, HCI and 
KNaC4a06'4H20 were purchased from Fisons, Loughborough. 
Ecoscint scintillation fluid was from National Diagnostics, Georgia, USA. 
2.1.3 Drugs 
Fentanyl citrate was gift from Janssen, Belgium. Naloxone hydrochloride 
was purchased from Sigma, Poole. N altrindole and norbinaltorphine 
were purchased from Semat. Morphine hydrochloride, codeine phosphate, methadone 
hydrochloride, and heroin hydrochloride were gifts from McFarlane Smith Edinburgh. 
Buprenorphine and its analogues were synthesised by Dr. J. W. Lewis, Bristol 
University, UK. 
2.1.4 Peptides and cAMP- bindingprotein 
DAMGO [D-AJa2, MePhe4, Gly(ol)5]enlcephalin and DPDPE [D-Pen2, D-
Pens]enkephalin were purchased from Sigrna, PooJe. 
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The cAMP-binding protein prepared from bovine adrenal glands was a gift from Dr. 
D. G. Lambert, Department of Anaesthesia, Leicester University. 
2.1.5 Cell culture media 
Minimum Essential Medium (with Eagle's salts), Dulbecco's Modified Eagle's 
Medium, L-Glutamine, penicillin/streptomycin, fungizone, HAT supplement 
(hypoxanthine, aminopterin and thymidine), trypsin/EDTA, foetal calf serum and new 
born calf serum were purchased from Gibco Laboratories, Paisley. 
2.1,6 Buffers 
The composition of Krebs solution used in the isolated tissue studies was as follows 
(mM): 
NaCI (118), NaHC03 (29), KCI (4.7), CaCh '2H20 (2.5), MgS04,H20 (4.0), 
KH2P04 (1.2) and Glucose (11.1), pH 7.4. MgS04'7H20 was omitted for the mouse 
vasa deferentia. 
The Krebs/HEPES buffer used in cAMP assays and whole cell ligand binding assays 
contained (mM): 
NaCI (118), NaHC03 (25), KCI (4.7), CaCh2H20(2.5), MgS04.7HzO (1.2), KH2P04 
(1.2) and Glucose (11.7) and HEPES (10), pH 7.4. 
The buffer used for membrane binding assays was Tris-HCI (50rnM), pH 7.4. 
The buffer used in CSSl-GTPyS binding assays contained (mM): 
NaCl (100), MgClz,6H20 (10) and HEPES (20), pH 7.4. 
Adsorption buffer used in cyclic AMP assays contained (mM): 
EDTA(4), BSA(4mg/mJ), and Tris (50) adjusted to pH 7.4 using concentrated 
hydrochloric acid. 
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2.1.7 Animals 
Male Dunkin-Hartley guinea-pigs (250-500g), were bought from David Hall, 
Newchurch, Burton-on-Tent. 
Male CSI mice (25-30g), were purchased from Nottingham University Medical 
School. 
Animals were fed on a standard laboratory diet and kept on 12h light/dark cycle at a 
temperature of 20°C. 
2.1.8 Equipment 
Isolated tissue assays: 
Grass 88 Stimulator, Grass Medical Instruments, Quincy, Mass., U.S.A. 
Harvard Universal Oscillograph and transducers, Harvard Apparatus Limited 
Edenbridge, Kent. 
Ligand binding and intracellular assays: 
Brandel cell harvester M-48R, Gaithersburg, U.S.A.Liquid scintillation counter, either 
MINAXI TRI-CARE 4000 series, United Technologies Packard, Pangbourne or 1215 
Rackbeta, LKB Wallac, Milton Keynes. 
Polytron PT 10-35 Homogeniser, Kinematica GmbH, Littau, Switzerland. 
Tissue tearoT, Biospec products, Banlesville, OK, U.S.A. 
Ultracentrifuge, Optima TLlOO, Beckman, High Wycombe. 
Centrifuge, Universal 1200 Httich, TuttIingen, Germany. 
Micro-centrifuge, Model 320, Quickfit Instrumentation, Stone. 
Whatrnan GF/B fllter strips, Whatrnan, Maidstone. 
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Cell cuI ture: 
Centrifuge, FP-51O, Labsystems Oy, Finland. 
Class IT Microbiological Safety Cabinet, Walker Safety Cabinets Ltd. Glossop, 
Derbyshire. 
Incubator, GC4, Grant Instruments, Cambridge. 
Powerpette, Jencons Scientific Ltd, Leighton Buzzard. 
Tissue culture plastics, Gibco Laboratories, Paisley. 
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2.2 Methods 
2.2.1 Isolated tissue studies 
(a) Mouse vas deferentia 
Male CSI albino mice (25-30g) were killed by cervical dislocation. The vasa deferentia 
were removed and mounted in 3ml organ baths, containing Krebs solution (minus 
MgS04.7HzO). An initial resting tension was set up at 0.5g. Tissues were bathed 
constantly in buffer solution at 37°C, and aerated with 5% COzin 95% O2 • 
After a recovery period of 90 minutes, field stimulation between platinum ring 
electrodes at upper and lower ends of the bath was initiated, consisting of three pulses 
at supramaximal voltage of I s duration at intervals of 250 ms. The contractions were 
recorded isotonically. 
(b) Guinea-pig myenteric plexus-longitudinal muscle 
Male Dunkin-Hartley guinea-pigs (300-400g) were killed by cervical dislocation. The 
ileum was immediately removed and placed in Krebs solution. Strips of myenteric 
plexus-longitudinal muscle were prepared and mounted (approximately length of 5 cm) 
in 3ml organ bath. The resting tension was set at l.Og. Tissues were bathed in Krebs 
solution at a constant 37°C and aerated with 5% COz in 95% Oz. 
After a recovery period of 90 minutes, tissues were stimulated using square wave 
OAms pulses of supramaximal voltage, and a frequency of 0.16 Hz. The contractions 
were recorded isotonically. 
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(c) Determination of agonist potencies 
Tissues were stimulated as described above until even contractions were maintained. 
Agonists were then added cumulatively, until the inhibition of contraction was 
maximal; then the stimulation was stoped and the tissue was washed with an overflow 
of Krebs solution. The tissue was stimulated at regular intervals, during which 
continuous washing was undertaken, until maximal contraction was restored. The 
tissue was allowed to rest for approximately 15 min prior to the next application of 
agonist. 
The concentration of agonist required to reduce the twitch height to half the maximal 
value (ICso) was calculated from dose-response curves, to give agonist potencies. 
(d) Measurement of antagonist affinities 
The tissue was incubated with the antagonist for the following lengths of time prior to 
the addition of the agonist: 
Naloxone 
Naltrindole 
nor-BNI 
15 minutes (mouse vas deferens) 
15 minutes (mouse vas deferens) 
30 minutes (guinea-pig ileum) 
Dose-response curves of the agonists were obtained before the addition of the 
antagonists and then repeated in the presence of antagonist. Antagonist affinities were 
determined as equilibrium dissociation constants (Ke values). Ke values were 
determined with a single dose of antagonist using the equation: 
[antagonist] 
Ke= DR-l 
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where DR = ICso in the presence of antagonist / ICso in the absence of antagonist 
[Kenakin, 1983] 
2.2.2 Ligand-binding studies 
(a) Preparation of homogenates 
Mouse brain 
Mice were killed by cervical dislocation and the brains removed, weighed and 
homogenised in Tris buffer for 10 seconds using a polytron homogeniser set at unit 
7.0. After centrifugation (25000g, 15 min) at 4°C, the pellet was resuspended in 
lOxvolume Tris buffer and incubated at 37°C for 30 minutes to remove endogenous 
ligands. The homogenates were recentrifuged as above and then the pellet 
resuspended in 1/60 weight / volume in Tris buffer. The final protein concentration of 
brain tissue was determined by the Lowry method and adjusted to approximately 
concentration ofO.5mglml [Lowry et, aI., 1951]. 
SH-SY5Y human neuroblastoma cells 
The SH-SY5Y cell line was kindly donated by Dr. D Lambert, Department of 
Anaesthesia, Leicester University. Cells were grown in. Minimum Essential Medium 
(MEM) supplemented with 2% foetal calf serum, 10% new born calf serum, 2.51lg/ml 
amphotericin B (fungizone), 50Ulml penicillin, 50111 streptomycin and L-glutamine 
(254Ilglml) at 37°C in a humidified 5% CO2 atmosphere. Cells were passaged when 
confluent (using 500llglml trypsin and 200llglml EDTA in a physiological solution) 
and fed three times weekly. 
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NO 1 08-1 5 neuroblastoma x glioma hybrid cells 
NOI08-15 cells were kindly provided by Dr. M. Keen, Dept. of Phannacology, 
University of Birmingham. The cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with HAT [hypoxanthine (13.6Jlg/mI), aminopterin 
(0.17Jlg/mI) and thymidine (3.88Jlg/mI)] at 37°C in a 5% C02 atmosphere. Cells were 
passaged when confluent (by gentle mechanical agitation) and fed every day, with the 
exception of Day 1 after sub-culture. 
Cell membrane preparations 
Confluent monolayers of SH-SY5Y cells were harvested in HEPES (20mM) buffered 
saline containing 0.02% (w/v) EDTA. NGl08-15 cells were harvested in Dulbecco's 
Modified Eagle Medium. Harvested cells were centrifuged at 250g for 2 min at room 
temperature and the pellet of cells was resuspended in the appropriate buffer (Tris 
buffer or Tris buffer plus Na+ and GTPyS or CSS]-GTPyS assay buffer). Membranes 
were prepared by treatment with a tissue tearor (2x5s, 30,OOOrpm),and collected by 
centrifugation (50,OOOg, 15min, 4°C). The pellet was resuspended in the appropriate 
buffer using the tissue tearor (2xls, 5000rpm), and then recentrifuged as before. The 
resulting pellet of membranes was re suspended in the appropriate assay buffer 
(approximatly one flask to 35mIs), as required, at a protein concentration of 0.25 
mg/ml (Lowry et,al., 1951J. 
(b) Competitive binding assays 
To 960Jll of the final appropriate homogenate prepared as above, 20Jll aliquots of 
unlabelled competing ligand in increasing concentrations, and 20Jl1 of a labelled ligand 
were added to a final volume of lmI. Total binding was determined by adding 20111 of 
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the labelled ligand to the homogenate in the absence of any competing ligand, and non-
specific binding was determined in the presence of IOJlM naloxone. The 
concentrations of labelled ligand used in the assays were approximately as follows: 
CH]DAMGO: InM, [3H]DPDPE: 2nM, CH]CI977: O.5nM, CHldiprenorphine: 
O.5nM. 
The assay solutions were incubated for 40 min at 25°C, then fIltered rapidly through 
Whatman GF/B glass filters under vacuum (the filter paper was pre-soaked in Tris-HCI 
buffer for at least 15 min) and washed twice with 4mIs of ice-cold Tris-HCI buffer. 
The filter papers were placed in scintillation vials to which Ecoscint was added and the 
amount of bound tritiated ligand was determined by using a liquid scintillation counter. 
The ICso value for test compounds were determined from the displacement curves 
which were drawn using" Cricket .. graph. The equilibrium inhibition constants (Ki 
values) were calculated according to the equation of Cheng and Prusoff [1973]. 
ICsoxKD Ki = ....:...:-'---'--
KD+[L*] 
where KD is the equilibrium dissociation constant of the labelled ligand and [L *] is 
the concentration of labelled ligand used in the assay. 
(c) Saturation binding assays 
SH-SY5Y or NG 108-15 cell membrane homogenates were incubated at 25°C for 40 
min with varying concentration of tritiated ligand (0.OO5-20nM) in the absence or 
presence of IOIlM naloxone to define non-specific binding. The remaining procedures 
were the same as described for the displacement binding assay. 
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The binding capacities (Bm",,) and equilibrium dissociation constant (Ko values) were 
calculated from the computer programme LIGAND [Munson and Rodbard, 1980], 
and represented graphically as Scatchard plot, thus: 
B Bmax B 
F KD KD 
where B is radioligand bound to receptor, F is free radioligand, Ko is equilibrium 
dissociation constant of radioligand and Bmax is the maximal number of binding sites. 
A plot of BIF versus B gives a straight line with a slope of l/Ko and an intercept with 
the abscissa of Bmax. 
2.2.3 eSSl-GTPyS binding assays 
SH-SY5Y cell membrane preparations were prepared as described in section 2.2. 
Membrane homogenates (lOO-200Jlg) were incubated in "GTPyS binding assay 
buffer" containing lOOpM eSSl-GTPyS, 3JlM GDP and varying concentration of 
opioid ligand, for 1 hour at 30°C. The solution was then rapidly vacuum-flltered and 
washed twice with 4 mls of ice-cold buffer. The filter papers were placed in Ecoscint 
scintillation fluid, and the amount of bound radioactivity was determined by counting 
in the C-14 channel of a liquid scintilation counter. 
The amount of stimulated eSSl-GTPyS binding is given as a percentage of the 
stimulation evoked by 3JlM fentanyl. The ECso (concentration affording a 50% 
response) value was calculated from the concentration-response curve (drawn by 
"Cricket" graph) and the basal eSS]-GTPyS binding was expressed as frnol esS]-
GTPyS bound !mg protein. 
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2.2.4 Cyclic AMP assays 
SH-SYSY cells were harvested by a brief exposure to HEPES (10mM) buffered saline 
containing EDT A (0.5rnM), and centrifuged at 500g for 2min. The pellets were 
resuspended in Krebs/HEPES buffer at a protein concentration of approximate 
2mg/ml, then the whole cell suspension (approximatJy 300Jlg) were incubated in the 
total volume 300JlI containing isobutymethyxanthine (lrnM), forskolin (lOJlM) and 
various concentrations of opioid agonist. The incubation was performed at 37°C for 
15 min. The reaction was terminated by addition of 20JlI HCI (lOM), 20Jll NaOH 
(lOM) and 180 JlI Tris (lM) pH 7.4. After centrifugation (lSOOg, 2min), cAMP in the 
supernatant was determined using a protein binding method [Brown et al.1971J. 
The protein binding method relies on the competition between eHJ-cAMP and 
unlabeled cAMP in the sample for a crude cAMP-binding protein prepared from 
bovine adrenal glands. Typically, SOJlI of reaction mixture or standard cAMP solution 
was incubated with 2 pmol eHJ-cAMP and binding protein at 4°C in the dark 
overnight. Non-specific binding of eHJ-cAMP was determined using a 12S-fold 
excess of unlabelled cAMP. Free eH]-cAMP was adsorbed by activated charcoal 
(lOmg/ml) suspended in adsorption buffer and removed by centrifugation (700g, 2min, 
room temprature). The amount of bound eHJ-cAMP in the supernatant was measured 
by counting an aliquot of the supernatant in the tritium channel of a liquid scintillation 
counter. 
cAMP content of the unknown samples was determined by interpolation from a 
standard curve and the measure of inhibition of cAMP formation was given as a 
percentage of the basal cAMP level. The ICso was calculated manually from the 
concentration-effect curves. 
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2.2.5 Molecular modelling: 
SYBYL (version 6.1, Tripos Associates, St. Louis, USA) was used to model the 
structures of buprenorphine and analogues using an Evans and Sutherland workstation 
with a unix computer. This allowed distances and angles in the structures to be 
accurately measured. 
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CHAPTER 3 RESULTS 
3.1 Isolated tissue studies 
3.1.1 Standard compounds 
The mouse vas deferens, containing 11, " and K opioid receptors and guinea-pig ileum 
containing functional 11 and 1\ opioid receptors, were used as in vitro models for the 
analysis of opioid receptor interactions [Kosterlitz and Waterfield, 1975]. The affinity 
and selectivity of several synthetic compounds were assayed in these test preparations. 
Standard selective agonists (DAMGO, DPDPE and U69593); and selective, non-
selective antagonists (naloxone, naltrindole and nor-BNI ) were tested in isolated 
tissue systems in order to obtain reference data and also to show the sensitivity of the 
tissue for use in the determination of agonist efficacy and selectivity. 
In the mouse vas deferens the compounds DAMGO, DPDPE, and U69593 all acted 
as full agonists, and afforded rcso values of 17.6+".0 nM, 0.93±O.04 nM and 28.4±3.6 
nM respectively. The affinity (as equilibrium dissociation constant values, Ke values) 
of naloxone, naltrindole and nor-BNI against these agonists were determined using 
single-dose method [Kosterlitz & Watt, 1968]. The data are summarised in Table 3.1. 
In the guinea-pig ileum, DAMGO and U69593 afforded ICso values of 5.6±1.8 nM 
and 2.4±O.9 nM respectively. The affinity (Ke values) of naloxone and nor-BNI 
against both compounds were obtained. The data are summarised in Table 3. 2 
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Table 3.1. The ICso values of DAMGO, DPDPE and U69593 & Ke values of 
naloxone, naltrindole and nor-BNI in the mouse vas deferens. 
DAMGO 
DPDPE 
U69593 
ICso(nM) 
17.6±2.0 
O.93iD.04 
28.4±3.6 
naloxone 
2.8iD.36 
54.4±2.1 
19.6±2.3 
Ke (nM) 
naltrindole 
6.5±1.7* 
O.14iD.03* 
17.3iD.7* 
nor-BNI 
32.8±L1* 
17.5±1.5* 
O.35iD.03* 
Values represent means ± s.e. mean where n~3. *data are taken from previous work 
in our laboratory [Bell, 1994]. 
Table 3. 2. The ICso values of DAMGO and U69593; and Ke values of 
DAMGO 
U69593 
naloxone and nor-BNI in the guinea-pig myenteric plexus-
longitudinal muscle. 
ICso(nM) 
5.6±1.8 
2.4iD.9 
Ke(nM) 
Naloxone 
2.09iD.54 * 
31.4±9.69* 
nor-BNI 
13.0±1.9* 
O.07±O.Ol* 
Values represent means ± s.e. mean where ~3. *data are taken from previous work in 
our laboratory [Bell, 1994]. 
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Figure 3.1 Dose-response curve for the inhibition of electrically 
induced contractions of mouse vas deferens by 
DAMGO (Cl). DPDPE (a) and U69593 (+). 
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Figure 3.2 Dose -response curve for the inhibition of electrically 
induced contractions of guinea-pig ileum by 
DAMGO (Cl) and U69593 (0), 
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3.1.2 Buprenorphine analogues 
A series of buprenorphine analogues were examined for their ability to inhibit the 
electrically-induced contractions in the mouse vas deferens and the guinea-pig ileum 
using the methods described in section 2.2.1. 
All compounds showed potent agonist activity in the mouse vas deferens (Figures 3.3-
3.14). There was little difference in potency between isomeric pair BU46 and BU47; 
and BU95 and BU96 (Table 3.3). In order to detennine the receptor through which 
the compounds were acting, the non-selective antagonist naloxone was used. The 
dose-response curves for the agonists and the shifts induced in the agonist dose-
response curves are shown in Figures 3.3-3.8. The naloxone affinity values obtained 
(Ke values) listed in Table 3.3 were in the range 14.8nM to 50.8nM, which suggested 
that these compounds acted via Ii or K receptors. For further confll1Ill\tion, the 0 
selective antagonist naltrindole was employed in this assay. The results shown in Table 
3.3 (Figures 3.9-3.14), are consistent with o..mediated responses, since the naltrindole 
Ke values were in the range 0.06 nM to 0.17 nM [Rogers et al., 1990] 
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Table 3.3 Agonist properties of buprenotphine analogues in the mouse 
vas deferens and their antagonism by naloxone and naltrindole. 
IC50 (nM) Ke (nM) 
BU Naltrindole 
compound 
46 1.3±O.3 O.17±O.O7 
47 3.6±O.3 0.09±O.02 
48 0.2±O.1 0.l1±O.02 
95 4.1±1.6 0.03±O.02 
96 7.2±O.2 0.10±0.02 
61 2.5±O.8 0.06±O.02 
values represent means ± s.e.mean where n2:3. 
Naloxone 
50.8±23 
28.0112 
41.6±13 
27.l±6.3 
14.8±O.3· 
24.5±4.5 
In the guinea-pig ileum assay, the compounds were also potent with ICso values 
ranging from 0.30nM to 3.70nM (Figures 3.15-3.20) as given in Table 3.4. There was 
a marked difference (10 fold) between the isomers BU46 and BU47. In order to 
determine the agonist site through which the compounds were acting, the selective 1C 
antagonist nor-BNI was used. The Ke values for nor-BNI determined against the 
various buprenorphine analogues are listed in Table 3.4 and are in line with 1C mediated 
response [Frankin & Traynor, 1991]], demonstrating that all of the buprenotphine 
analogues tested were acting via K receptors in this tissue. 
45 
Table 3.4 Agonist properties of buprenorphine analogues in the guinea-
pig myenteric plexus-longitudinal muscle and their antagonism 
by nor-BNI. 
BU 
compound 
46 
47 
48 
95 
96 
61 
ICso(nM) 
O.30±0.23 
3.64±1.3 
1.35±O.23 
2.02±O.2* 
3.7o±1.2* 
1.70±0.5* 
nor-BN! Ke (nM) 
O.03±o.03 
O.04±o.Ol 
O.I0±0.05 
O.l5±O.O7* 
O.O9±O.O1* 
O.12±O.O2* 
Values represent means ± s.e.mean where n~3. or *where n = 2 ± range. 
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Figure 3.4 Dose-response curve for the inhibition of elecoically 
induced contractions of mouse vas deferens by 
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Figure 3.6 Dose-response curve for the inhibition of eJecuically 
induced contractions of mouse vas deferens by 
BU95 in the absence (0) and presence (a) of 
100 nM naloxone. 
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Figure 3.8 Dose-response curve for the inhibition of electrically 
induced contractions of mouse vas deferens by 
BU61 in the absence (c ) and presence (. ) of 
100 nM naloxone. 
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Figure 3.9 Dose-response curve for the inhibition of electrically 
induced contractions of mouse vas deferens by 
BU46 in the absence (D) and presence (11) of 
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Figure 3.10 Dose-response curve for the inhibition of 
electrically induced contractions of mouse vas 
deferens by BU47 in the absence (Q) and 
presence (. ) of InM naltrindole. 
50 
100 
1000 
100 
o 
.01 
100 
80 
.<:: 
B 
.~ 
~ 50 
"0 
c:: 
0 40 
'0 
.~ 
.0 .~ 
.<:: 
.S 20 
~ 
0 
.1 
.1 10 
[BU48] nM 
Figure 3.11 Dose-response curve for the inhibition of 
elecnically induced contractions of mouse vas 
deferens by BU48 in the absence (0) and 
presence (11) of InM naltrindole. 
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Figure 3.12 Dose-response curve for the inhibition of 
elecnically induced contractions of mouse vas 
deferens by B U95 in the absence (Cl ) and . 
presence (. ) of lnM naltrindole. 
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Figure 3.13 Dose-response curve for the inhibition of 
electrically induced contractions of mouse vas 
deferens by BU96 in the absence (0) and 
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Figure 3.14 Dose-response curve for the inhibition of 
electrically induced contractions of mouse vas 
deferens by BU61 in the absence (a) and 
presence (.) of 1nM naltrindole. 
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Figure 3.15 Dose-response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU46 in the absence ( c) and presence 
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Figure 3.16 Dose-response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU47 in the absence (C) and presence 
(a) of InM n-BNI. 
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Figure 3,17 Dose'response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU48 in the absence (0 ) and presence 
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Figure 3.18 Dose-response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU95 in the absence (c ) and presence 
(El) of lnM n-BNI. 
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Figure 3.19 Dose-response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU96 in the absence ( Cl ) and presence 
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Figure 3.20 Dose-response curve for the inhibition of 
electrically induced contractions of guinea-pig 
ileum by BU61 in the absence (0) and presence 
(rI) of InM n-BNI. 
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3.2 Ligand-binding assays. 
3.2.1 Detennination of affinity of buprenorphine and analolWes at opioid 
receptoTS in brain tissue and in cultured cells. 
3.2.1 (a) Displacement of the J.l., 13 and K selective Jigands: 
eHl-DAMGO, eHl-DPDPE and eHJ-CI977 by buprenorphine 
and analogues in brain homogenates 
The competitive displacement of eHl-DAMGO, ['Hl-DPDPE and ['H)-CI977 by 
buprenorphine and analogues were conducted in mouse brain (or guinea-pig brain in 
the case of buprenorphine) homogenates according to the method described in section 
2.2. The graphs derived from these experiments are given in Figures 3.21-3.38. Ki 
values were calculated from ICsQ values and are listed in Table 3.5. The results 
indicated that the compounds all showed high affinity for J.l., /) and K receptoTS in brain 
tissue. 
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Table 3.5 Binding affinity of buprenorphine and analogues at /l. I) and 1C 
opioid receptors in mouse brain homogenates 
Ki (nM) 
BU 
Compound /l I) 
46 0.60±0.05 0.86±O.08 
47 0.88±O.20 1.45±O.19 
48 0.36±O.05 1.41±O.30 
95 0.48±O.19 1.41±O.09 
96 1.50±0.15 1.31±O.39 
61 0.55±O.06 1.78±O.l1 
buprenorphine 0.57±O.05* 1.30±0.O3* 
values represent means ± s.e. mean n~3. 
1C 
1.02±O.1 
2.75±O.1 
1.56±O.1 
3.20±1.0 
2.99±0.5 
1.79±O.1 
2.00±0.3* 
*Experiments were conducted in guinea-pig brain in our laboratory by J. Elliot 
3.2.1 (b) Displacement of eH]-DAMGO by buprenorphine 
and analogues in SH-SY5Y cell membranes 
The competitive displacement of eHJ-DAMGO by buprenorphine and analogues was 
conducted in SH-SY5Y cell membranes to examine the affinity of the compounds at 
the human Il receptor. The displacement curves are given in Figures 3.39-3.43. The Ki 
values obtained from these data listed in Table 3.6 were consistent with the data 
obtained from mouse brain tissue and confirmed all compounds to have high affinity at 
Il receptors. 
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Table 3.6 Binding afrmity of buprenorphine and analogues at 1.1. opioid 
receptors in SH-SY5Y cell membranes. 
BU Ki(nM) 
Compound 
46 O.35±o.03 
47 0.37±o.07 
95 0.69±o.03 
96 0.75±o.02 
buprenorphine 0.18±o.01 
Values represent means ± S.e. mean where n~3. 
3.2.1 (c) Displacement of eHJ-diprenorphine by buprenorphine in 
NOI08-15 cell membranes 
The competitive displacement of the opioid antagonist eH]-diprenorphine by 
buprenorphine was also studied at 0 receptors in NO 108-15 cell membranes in Tris 
buffer or Tris buffer containing 100 mM NaCI and 10 IlM OTPyS. The results are 
shown in Figure 3.44. The displacement of eHJ-diprenorphine (0.5 nM) by 
buprenorphine in Tris buffer alone afforded a Ki of 0.21±O.06 nM. When l00mM 
NaCI plus IOIlM GTPyS was included in the incubation buffer, the Ki value was only 
slightly increased to 0.37±o.08 nM. The results demonstrated that binding affInity of 
buprenorphine at 0 receptors does not alter in buffers which contain physiological 
concentrations of Na + ions. 
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3.2.2 Displacement of rJm-diprenorphine by morphine. heroin 
methadone and codeine in SH-SY5Y cell membranes 
The displacement of tHJ-diprenorphine by morphine, heroin, methadone and codeine 
was conducted in a binding assay buffer containing 100 mM NaCl, 10 mM MgClz in 
order to compare the binding affInity (Ki values) with the ECso values obtained in 
'functional' assays. The obtained Ki values for morphine, heroin, methadone and 
codeine were 624±34 nM, 1335±316 nM, 133±21 nM and 28145±1634 nM, 
respectively (Figure 3.45). 
3.2.3 Saturation binding assays in SH-SY5Y cell membranes 
There are many stocks of human neuroblastoma SH-SY5Y cells throughout the world 
and the receptor population of these may differ. The SH-SY5Y cell line is known to 
express both ~- and o-opioid receptors, with ~-opioid receptors predominating (Yu & 
Sadee, 1988]. However, earlier passage number (17-20) SH-SY5Y cells are reported 
to show different properties from later passage number SH-SY5Y cells (70-90) in 
electrophysiology experiments [G. Henderson, unpublished data]. In order to use the 
cells for future assays of ~-receptor affInity and effIcacy, experiments were designed to 
determine the opioid receptor population and characteristics on earlier passage number 
cells compared with the later passage number cells. The study employed [3Hl-
DAMGO and CHJ-DPDPE as radioligands. The results summarised in Table 7 
showed that the earlier passage number SH-SY5Y cells possessed a larger popUlation 
of /) receptors than that of ~ receptors, which is opposite to the situation in the later 
passage SH-SY5Y cells. Later passage cells containing higher population of ~ 
receptors were used in future experiments discribed in this thesis. 
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Table 3.7 Radioligand saturation binding in SH-SY5Y cell membranes 
Cell 
number 
earlier 
passages 
later 
passages 
eH]DAMGO 
Bmax 
(fmol/mg 
protein) 
34±8.6 
14o±ll* 
Ko(nM) 
1.36±O.43 
1.45±O.31* 
Bmax 
(fmol/mg 
protein) 
162±16 
56±11* 
eH]DPDPE 
KD(nM) 
1.26±O.24 
0.97±O.07* 
Values represent means ± s.e. mean 123. Assays were conducted at 25°C for 40 
min, Tris-HCI buffer pH 7.4. *Experiments performed in our laboratary by J. Elliot 
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Figure 3.21 Competitive displacement of specifically bound 
eH] DAMGO (InM) by BU46 in mouse brain 
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Figure 3.22 Competitive displacement of specifically bound 
eH] DAMGO (InM) by BU47 in mouse brain 
homogenates. 
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Figure 3.23 Competitive displacement of specifically bound 
[lHl DAMGO (InM) by BU48 in mouse brain 
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Figure 3.24 Competitive displacement of specifically bound 
eH] DAMGO (InM) by BU95 in mouse brain 
homogenates. 
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Figure 3.26 Competitive displacement of specifically bound 
eH] DAMGO (lnM) by BU61 in mouse brain 
homogenates. 
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Figure 3.27 Competitive displacement of specifically bound 
eH] DPDPE (2nM) by BU46 in mouse brain 
homogenates. 
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Figure 3.28 Competitive displacement of specifically bound 
eH] DPDPE (2nM) by BU47 in mouse brain 
homogenates. 
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Figure 3.29 Competitive displacement of specifically bound 
em DPDPE (2nM) by BU48 in mouse brain 
homogenates. 
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Figure 3.30 Competitive displacement of specifically bound 
em DPDPE (2nM) by BU95 in mouse brain 
homogenates. 
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Figure 3.31 Competitive displacement of specifically bound 
['H] DPDPE (2nM) by BU96 in mouse brain 
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Figure 3.32 Competitive displacement of specifically bound 
['H] DPDPE (2nM) by BU61 in mouse brain 
homogenates. 
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Figure 3.33 Competitive displacement of specifically bound 
eH] CI977 (O.SnM) by BU46 in mouse brain 
homogenates. 
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Figure 3.34 Competitive displacement of specifically bound 
[3H] CI977 (O.SnM) by BU47 in mouse brain 
homogenates. 
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Figure 3.35 Competitive displacement of specific bound 
eH] CI977 (O.5nM) by BU48 in mouse brain 
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Figure 3.36 Competitive displacement of specifically bound 
eH] CI977 (O.5nM) by BU95 in mouse brain 
homogenates. 
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Figure 3.38 Competitive displacement of specifically bound 
eH] CI977 (O.SnM) by BU61 in mouse brain 
homogenates. 
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Figure 3.39 Competitive displacement of specifically bound 
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Figure 3.40 Competitive displacement of specifically bound 
[3H]DAMGO (lnM) by BU46 in the SH-SY5Y 
cell membranes. 
70 
100 
100 
100 
bJ) 
c: 
:cl 80 ~ 
t) 
9 60 g 
A. 
'" 0 40 
~ 20 Cl 
e'< 
0 
100 
bJ) 
~ 
.S 80 
oD 
~ 9 60 g 
~ 
040 ~ 
~ 20 
e'< 
o 
.01 
.01 
• 1 10 100 
[BU47j nM 
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cell membranes. 
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Figure 3.42 Competitive displacement of specifically bound 
CHJDAMGO (lnM) by BU95 in the SH-SY5Y 
cell membranes. 
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Figure 3.43 Competitive displacement of specifically bound 
CH]DAMGO (lnM) by BU96 in the SH-SY5Y 
cell membranes. 
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Figure 3.44 Competitive displacement of specifically bound 
eH]diprenorphine (O.SnM) from membranes of 
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Figure 3.4S Competitive displacement of specifically bound 
CH]diprenorphine (O.SnM) from membranes of 
SH-SYSY cells by methadone (. ), morphine (0 ), 
heroin (A) and codeine (A) in eSS]GTPyS binding 
assay buffer. 
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Figure 3.47 A representative graph showing saturation eH] DPDPE binding to earlier 
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Scatchard plot. 
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3.3 Intracellular assays using SH·SYSY cells 
3.3.1 cyclic AMP assays 
3.3.1 (a) Use of DAM GO as a standard compound to determine the 
sensitivity of cAMP assays 
In SH-SY5Y cells. inhibition of cAMP formation by a range of Jl opioids has 
illustrated that cAMP assays offer a good system in which the functional response of Jl 
opioid agonists can be measured [Lamben etal..1993]. 
In this experiment. the Jl agonist DAMGO has been used as a standard compound to 
show the sensitivity of the assay. Assays were conducted using the method described 
in section 2.3. The maximal inhibition of forskolin stimulated cAMP formation by 
DAMGO was about 50% of the basal level. and the leso value was 90 nM [Figure 
3,48]. which is in agreement with the results obtained by Lambert et al. [1993]. 
3.3.1 Cb) Buprenorphine analogues evaluated using cAMP assay 
Two isomer pairs BU46 and BU47; BU9S and BU96 were tested in the cAMP assay. 
All compounds inhibited forskolin stimulated cAMP levels (Figures 3.49-3.52). Both 
the maximal inhibition and the ICso values obtained are listed in Table 3.8 and 
compared with DAMGO. The data showed that the efficacy of all compounds tested 
was lower then that of DAMGO in this cell system. From the ICso values. it can be 
seen that all the buprenorphine analogues tested are potent agonists at ).L opioid 
receptors. 
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Table. 3.8 IC50 values and maximal inhibition of cAMP fonnation in 
SH-SY5Y cells by DAMGO and buprenOIphine analogues 
BU 
compound 
IC50 (nM) maximal effect 
DAMGO 
BU46 
BU47 
BU95 
BU96 
96±4.6 
l5±4.5 
17±3.5 
20±4.2 
28+3.2 
1 
0.6 
0.6 
0.5 
0.5 
Values represent mean ± range n=2 with exception of DAMGO where n=3. 
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Figure 3.48 Inhibition of forskolin-stimulated adenylyl 
cyclase activity by DAMGO in SH-SY5Y whole 
cells. Forskolin stimulated adenylyl cyclase 
activity was 63±4.3 fmol / mg protein / min. 
f 1 
I 
10 100 
[BU461 nM 
1000 10000 
Figure 3.49 Inhibition of forskolin-stimulated adenylyl 
cyclase activity by BU46 in SH-SY5Y whole 
cells. Forskolin stimulated adenylyl cyclase 
activity was 67.8±5.6 fmoll mg protein / min. 
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Figure 3.50 Inhibition offorskolin-stimulated adenylyl 
cyclase activity by BU47 in SH-SY5Y whole 
cells. Forskolin stimulated adenylyl cyclase 
activity was 67.8±5.6 fmol / mg protein / min. 
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Figure 3.51 Inhibition offorskolin-stimulated adenylyl 
cyclase activity by BU95 in SH-SY5Y whole 
cells. Forskolin stimulated adenylyl cyclase 
activity was 70;2±4.3 fmol / mg protein / min. 
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Figure 3.52 Inhibition of forskolin-stimulated adenylyl 
cyclase activity by BU96 in SH-SY5Y whole 
cells. Forskolin stimulated adenylyl cyclase 
activity was 70.2±4.3 fmol / mg protein / min. 
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3.3.2 r'sSl-GTPyS binding assay 
3.3.2 (a) [3sS]_GTPyS binding assay as a sensitive method for the 
determination of opioid efficacy 
J.l Opioid agonists have been shown to modulate ['sS]-GTPyS binding in SH-SY5Y 
cell membranes in a naloxone-reversible manner [Traynor & Nahorski, 1995]. 
Therefore, using this assay the efficacy and potency of J.l opioids can be quickly 
determined in SH-SY5Y cells and the assay can potentially be used to screen large 
numbers of opiates. 
Initial experiment were conducted to demonstrate that similar results could be 
achieved to those originally reported by Traynor & Nahorski [1995]. The J.l opioid 
agonist DAMGO afforded an ECso value of 8.3±O.8 nM (Figure 3.53). 
In the same manner, concentration-effect curves for the J.l opioid agonists morphine, 
methadone, heroin and codeine were conducted (Figure 3.54).The maximal stimulation 
of ['sS]-GTPyS binding and the potency of the compounds obtained are listed in Table 
3.9. 
3.3.2 (b) Buprenorphine and analogues examined using the ['sS]-GTPyS 
binding assay 
The maximal effects (compare to fentanyl) and ECso values obtained for buprenorphine 
and analogues are listed in Table 3.10. From the data, it can be seen that 
buprenorphine and analogues are all potent partial agonists at J.l opioid receptors. 
However, the efficacy of buprenorphine in this system is slightly higher then that of its 
analogues [Figures 3.55-3.62]. The agonist activity of BU47 was readily blocked by 
the antagonist naloxone affording a Ke value of 3.3±O.7 nM, indicating the effect is 
mediated via J.l receptors. 
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For comparison a futher derivative BU4 (Figurel.l1), which contains an N-Me instead 
of N-CPM was examined. This compound was a potent full agonist. 
Table 3.9 ECso values and maximal effects of stimulation of eSS]-GTPyS binding 
to membranes from SH-SY5Y cells by DAMGO, morphine, methadone, 
heroin and codeine 
Compound ECso(nM) Maximal effect 
DAMGO 8.4±1.8 1.1 
Morphine 31.8±3.2 1.0 
Methadone 19.9±2.9 1.0 
Heroin 316±28 1.1 
Codeine 5309±430 1.1 
Fentanyl* 15.2±3.0 1.0 
Values represent mean ± s.e. n;::3. *Values are nonnalized to the stimulation of esS]-
GTPyS binding caused by 3 IlM fentanyl (maximal effect =1.0). *Fentanyl data are 
taken from Traynor & Nahorski [1995]. 
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Table 3.10 ECso values and maximal effects of stimulation of esS]- GTPyS binding 
to membranes from SH-SY5Y cells by buprenorphine and analogues 
Compound ECso Maximal effect Naloxone Ke 
buprenorp hine 0.1 8±O. 10 0.73 
BU46 0.2I±O.04 0.44 
BU47 OAO±O.07 0.44 3.3±O.7 
BU48 0.23±O.04 0.38 
BU95 0.33±O.06 0.53 
BU96 0.56±O.08 0.53 
BU6l 0.26±O.05 0.36 
BU4 0.18±O.03 1.0 
Values represent mean ± s.e.mean n~3. Values are normalized to the stimulation of 
eSS]-GTPyS binding caused by 311M fentanyl (maximal effect '= 1.0) 
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Figure 3.53 Stimulation of eSS]GTPyS binding to membranes of 
SH-SY5Y cells by DAM GO. Control binding of 
eSS]GTPyS was 40±3.6 fmol/mg protein in the 
absence offentanyl and 76±5.7 fmol/mg protein in the 
presence of fentanyl (3iJ.M). 
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Figure 3.54 Stimulation of eSS]GTPyS binding to membranes of 
SH-SY5Y cells by methadone (.), morphine (0), 
heroin (a) and codeine ( "). Control binding of 
eSS]GTPyS was 40±3.6 fmol/mg protein in the 
absence of fentanyl and 76±5.7 fmol/rng protein in the 
presence of fentanyl (3iJ.M). 
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Figure 3.55 Stimulation of eSS]GTPyS binding to membranes of 
SH-SY5Y cells by buprenorphine. Control binding of 
eSS]GTPyS was 39±3.2 fmol/mg protein in the 
absence of fentanyl and 63±3.6 fmol/mg protein in the 
presence of fentanyl (3f.lM). 
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Figure 3.56 Stimulation of eSS]GTPyS binding to membranes of 
SH-SY5Y cells by BU4. Control binding of 
eSS]GTPyS was 40±3.6 fmol/mg protein in the 
absence of fentanyl and 7615.7 fmol/mg protein in the 
presence of fentanyl (3f.lM). 
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Figure 3.57 
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Stimulation of [,5S]GTPyS binding to membranes of 
SH-SY5Y cells by BU46. Control binding of 
[,sS]GTPyS was 44±4.7 fmoVmg protein in the 
aosence of fentanyl and 78±6.3 fmoVmg protein in the 
presence of fentanyl (3I1M). 
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Figure 3.58 Stimulation of [,sS]GTPyS binding to membranes of 
SH-SY5Y cells by BU95. Control binding of 
[,sS]GTPyS was 42±2.2 fmoVmg protein in the 
absence of fentanyl and 78±4.2 fmoVmg protein in the 
presence of fentanyl (3I1M). 
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Figure 3.59 Stimulation of [3SS]GTPyS binding to membranes of 
SH-SY5Y cells by BU47 in the absence ( Cl ) and 
presence (. ) of 10 nM naloxone. Control binding of 
[,sS]GTPyS was 44±4.7 fmoVmg protein in the 
absence of fentanyl and 78±6.3 fmoVmg protein in the 
presence offentanyl (3flM). 
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Figure 3.60 Stimulation of [,sS]GTPyS binding to membranes of 
SH-SY5Y cells by BU48. Control binding of 
[,sS]GTPyS was 49±5.2 fmoVrng protein in the 
absence of fentanyl and 83±7.3 fmoVrng protein in the 
presence of fentanyl (3IlM). 
87 
1000 
1000 
100 
c:: 
0 
'D 80 
'" '3
.§ 
60 
'" Ol 
.§ 
40 ~ 
S 
ll'< 20 
0 
100 
c:: 
0 80 
'0 
'" '3 
.§ 60 
'" Ol 
8 40 .~ 
8 
ll'< 20 
0 
.01 .1 
Figure 3.61 
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Stimulation of eSS]GTF-yS binding to membranes of 
SH-SY5Y cells by BV96. Control binding of 
eSS]GTF-yS was 42±2.2 fmoVmg protein in the 
absence of fentanyl and 78±4.2 fmoVmg protein in the 
presence of fentanyl (3flM). 
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Figure 3.62 Stimulation of eSS]GTF-yS binding to membranes of 
SH-SY5Y cells by BV61. Control binding of 
eSS]GTF-yS was 400.3 fmoVmg protein in the 
absence of fentanyl and 79±4.8 fmoVmg protein in the 
presence of fentanyl (WM). 
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Chapter 4.0 Discussion and Conclusions 
The presence of two lipophilic agonist binding sites for the N-cyclopropymethyl 
orvinols; one above the ring system associated with 11 agonism and one below Cs 
associated with K agonism, has been proposed [Coop, 1995]. Buprenorphine is an N-
cyclopropylmethyl orvinol which is a potent analgesic agent. In vivo, this compound is 
a partial agonist at ~ opioid receptors and a potent antagonist at K receptors [Rance, 
1979]. To investigate factors detennining this unique ~ partial agonism/ K antagonism 
profile, analogues of buprenorphine where the conformation about C(7)-C(19) is 
constrained into rings, have been synthesised. This should allow examination of the 
influence of the spatial position of the tertiary alcohol function. In the present studies 
seven conformationally restrained analogues have been tested for their affinity and 
efficacy in in vitro experiments. In the constrained molecules the OH and additional 
alkyl ring are fixed below the buprenorphine ring system and hence the ring methylenes 
are available to interact with the putative K-agonist site, but not the proposed 11-
agonist site (Diagram 4.1). 
mu lipophilic binding site 
OMe 
C19.-\ / 
OH / kappa lipophilic binding site 
Diagram 4.1 Partial structure of BU47 showing how the additional alkyl ring 
might interact with a proposed kappa lipophilic binding site. 
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(1) Binding assays 
(a) buprenorphine 
The in vivo K-antagonist activity of buprenorphine occurs over the same dose range 
that buprenorphine exhibits partial ~ agonist activity in rats [Leander, 1987]. In several 
in vivo a~says buprenorphine exhibits a bell-shaped dose-response curve with the 
agonist response being reversed at higher concentration [Cowan et al., 1977]. This 
observed phannacological phenomenon is unlikely to be explained by differential 
affmity for opioid receptor types, since in vitro buprenorphine has a similar high 
affmity for ~. Sand K receptors, all being in the low nanomolar range, namely 
0.57±O.05 nM at ~ receptors, 1.30±0.03 nM at S receptors and 2.00±0.30 nM at K 
receptors respectively [ElIiot, 1991]. However these values were obtained in Tris 
buffer which favours high agonist affmity states of the receptor and does not 
necessarily indicate affinity under more physiological condition [Carroll et aI., 1988]. 
The affinity of buprenorphine at both Jl and K receptors shifts just 2-fold in the 
presence of 25 mM Na + suggesting buprenorphine may have same affinity at ~ and K 
receptors under physiological conditions [Elliot, 1991]. 
The activity of buprenorphine at S receptors, paticularly in buffers containing Na+ has 
not been much studied to date, hence an attempt was made to explain the bell-shaped 
dose-response curves seen in vivo by an action of buprenorphine at S receptors. The 
hypothesis was proposed that at the lower concentrations, buprenorphine acts via Jl 
receptors to elicit agonist activity whereas in the higher concentrations, buprenorphine 
could act via an agonist action at S receptors to elicit the reversal effect by a 
mechanism involving physiological antagonism. This would require buprenorphine to 
have a lower affinity at S receptors and thus require higher concentrations to show an 
effect. The assays were performed for the following two reasons. Firstly. the true 
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differences in affinity of buprenorphine at opioid receptor types may not be revealed in 
the normal binding assay conditions of low ionic strength Tris buffer [Carroll et al., 
1988]; secondly, the agonist and antagonist properties of opioids may be revealed by 
the effects of guanyl nucleotides and sodium on the affinity of the compound for their 
receptors. Data from binding assays confirmed that at 0 receptors buprenorphine had a 
high affmity, similar to its affmity at 11 receptors, in Tris buffer. The binding affinity of 
buprenorphine at 0 receptors under more physiological conditions, i.e. in a buffer 
containing the guanosineS-triphosphate stable analogue GTPyS and a physiological 
concentration of Na+ was therefore tested. 
The results showed that the Ki value of buprenorphine at 0 receptors in Tris buffer 
alone was O.21±O.06 nM, but in the buffer containing GTPyS and Na+ was O.37±O.08 
nM; that is no significant difference was found. This result demonstrated that the 
binding affinity of buprenorphine at 0 receptors did not alter in the physiological 
conditions similar to the observations at 11 and K receptors. This is in line with the 
results of similar experiments using mouse brain carried out by Villiger et al. [1984] 
which yielded the conclusion that binding affinity of buprenorphine is either increased 
or not affected by guanosine-5'-triphosphate and physiological concentrations of Na+ 
at 11, 0 or K receptors. Thus the in vivo pharmacological effects of buprenorphine are 
unlikely to be readily explained by simple analysis of ligand-binding assays, even in 
physiological buffers. 
(b) Buprenorphine analogues 
The binding affinity of the ring constrained buprenorphine analogues was examined in 
homogenates of mouse brains and SH-SY5Y human neuroblastoma cells in Tris 
buffer. All the buprenorphine analogues tested showed similar binding profiles. The 
compounds possessed high affinity at the three opioid receptors, with Ki values in the 
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low nM range between 0.36±O.05 nM for compound BU48 at 11 receptors to 3.2o±1.0 
nM for compound BU95 at K receptors. All six compounds were slightly 11 selective, 
and affmity was in the order 11>0>1(. This was consistent with the parent compound 
buprenorphine [Elliot, 1991]. It can be concluded that the position of tertiary alcohol 
function does not play an important role in controlling receptor-binding affinity. 
(2) Isolated tissue assays 
(a) Assays in the mouse vas deferens preparation 
The compounds all showed potent agonist activity with Ieso values in the range 0.2 
nM for BU48 to 7.2 nM for BU96. The compounds were all full agonists in this 
preparation, since the maximum inhibition of the electrically-induced conlractions of 
the mouse vas deferens was always greater than 90% of the conlrol twitch height 
Since the mouse vas deferens prepara tion contains 11, 0 and K receptors with 1) 
receptor predominating [Leslie, 1987], compounds with agonist activity at different 
receptors are likely to show responses via 0 receptors preferentially. 
The non-selective antagonist naloxone was used initially to determine the selectivity of 
the compounds. Antagonism by naloxone afforded Ke values in the range 14.8±O.3 
nM for compound BU96 to 50.8±23 nM for compound BU47, which suggested that 
the action of these compounds is associated with 0 or K receptors, but certainly not 11 
receptors where the expected Ke value is in the range 1-3 nM [Leslie, 1987]. The 0 
selective antagonist naltrindole was then chosen to discriminate I) actions from K 
mediated effects. The naltrindole Ke values were in the range 0.03 nM for compound 
BU95 to 0.17 nM for compound BU46, which were consistent with antagonism of 0-
mediated responses [Rogers et aI., 1990]. The conclusion can be drawn that the 
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buprenorphine analogues tested were all potent 0 full agonists in the mouse vas 
deferens preparation. However, there was no obvious difference in efficacy and 
potency between the isomeric pairs, although the least strained ring derivative 
compound BU48, where a 6-membered ring is included rather than a 5-membered 
ring, was the most potent with its Iesa value (0.2±O.1 nM) being much lower than its 
Ki value (1.41±O.3 nM) at 0 receptors in the binding assay. This is in contrast with the 
other compounds in which the Ki and Tesa values were similar (Table 4.1). Hence the 
position of the tertiary OH may play a role in the determination of efficacy and 
potency at 0 receptors, although the higher potency and efficacy of BU48 may related 
to the 6-membered ring itself in this compound. 
Table 4.1 Iesa / Ki of buprenorphine analogues at 0 and K receptors 
BU 
compound 
BU46 
BU47 
BU48 
BU95 
BU96 
BU61 
Tesa / Ki 
(8) 
1.51 
2.50 
0.14 
2.90 
5.49 
1.40 
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Iesa / Ki 
(K) 
0.29 
1.32 
0.87 
0.63 
1.25 
0.95 
(b) Assays in the guinea-pig ileum preparation 
The parent compound buprenorphine shows an agonist proftle in the guinea-pig 
preparations which is relatively resistant to naloxone [Schulz & Herz, 19761_ 
However, much in vivo evidence suggests a ~ agonism and lC antagonism proftle for 
buprenorphine. 
In the guinea-pig ileum preparation all ring constrained buprenorphine analogues 
tested acted as a potent full agonists with the rcso values in the range O.30±0.23 nM 
for compound BU46 to 3.70±0.20 nM for compound BU96. Since the guinea-pig 
ileum preparation contains 11 and K receptors, the lC selective antagonist nor-BN! was 
used to show the receptor through which the compounds were acting. The nor-BN! 
Ke values were in the range O.03±O.03 nM to O.15±O.07 nM, which is in line with lC-
mediated responses [Franklin & Traynor, 1991]. 
The isomers BU46 and BU47 showed a lO-fold difference in potency with the ICso 
values being O.30±0.23 nM for BU46, and 3.64±1.30 nM for BU47. In contrast, only a 
2-fold difference was seen in binding affinity with Ki values being l.02±O.10 nM for 
BU46, and 2.75±O.1O nM for BU47. This suggests that the position of tertiary OH 
plays a role in the determination of efficacy and potency at lC sites. However, this is not 
the case for the isomers BU95 and BU96 that had similar potency which was in line 
with the weaker BU47. Thus the introduction of methyl groups in compounds BU95 
and BU96 appears to mask differences in potency and efficacy. 
Since the guinea-pig ileum preparation possesses a higher 11 receptor density than lC 
receptor density [Leslie, 1987], the fact that the lC activity of the buprenorphine 
analogues was seen in this tissue suggests that the compounds have no, or only weak 
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activity, at f.l receptors. In order to examine whether the compounds possess any 
intrinsic activity at 11 receptors, intracellular assays were performed as a measure of 
function in a system not possessing K receptors, namely human neuroblastoma, SH-
SY5Y cells. 
(3) Intracellular assays 
The most commonly used intracellular assay for opioid agonism is the inhibition of 
stimulated cyclic AMP accumulation. Although the assay indicates the efficacy and 
potency of the opioid compounds in several cell lines and brain tissues, the sensitivity 
of the assay is not always very good. Moreover, this assay does not lend itself to large 
scale drug screening due to the small magnitude of the response [Costa et al., 1991]. 
In SH-SY5Y cells, which possess !1 opioid receptors predominantly, the signal to 
noise ratio for cyclic AMP assay was small, even for a fulll1-agonist such as DAMGO. 
The maximum inhibition caused by DAMGO was only about 50% of the basal levels, 
which is in agreement with previous studies (Lambert et al., 1993], hence compounds 
with weak partial agonist activity cannot be distinguished readily in this assay. As an 
alternative, the [3sS]_GTPyS binding assay has been investigated at opioid receptors 
recently [Traynor & Nahorski, 1995]. In this assay, the ability of !1 opioid agonists to 
activate G proteins, has been measured as the binding of eSS]-GTPyS to membranes 
from human neuroblastoma SH-SY5Y cells. In these cells the maximum stimulation of 
[3sS]_GTPyS binding caused by !1 full agonist fentanyl (3I1M) is about 70-100% 
increase over the basal levels, and it has been shown that DAMGO and fentanyl are 
full agonists and pentazocine is a partial agonist at !1 receptors in this system [Traynor 
& Nahorski, 1995]. 
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The standard compounds, morphine, heroin, codeine and methadone were examined 
using the ['sS]-GTPyS binding assay in SH-SY5Y cells. The results showed that 
morphine, heroin, codeine and methadone were all full agonists at 11 receptors, since 
the maximal stimulation of the [,sSl-GTPyS binding caused by these compounds was 
similar to that of the full agonist fentanyl. However, codeine was the least potent and 
ECso values of 19.9±2.9 nM, 31.8±3.2 nM, 316±28 nM and 5309±430 nM for 
methadone, morphine, heroin and codeine respectively were obtained. In ligand-
binding assays Ki values for methadone, morphine, heroin and codeine under the 
conditions of the GTPyS assay were 133±21 nM, 624±34 nM, 1335±316 nM, and 
28145±1634 nM. The different potency and the different Ki values in binding of 
morphine, heroin and codeine indicated that heroin and codeine are not metabolised to 
morphine to elicit their pharmacological effects under these assay conditions. Indeed, 
no metabolism of these compounds was observed in SH-SY5Y cell homogenates 
[Naweed, 1995]. Thus the replacement of the 3-0H in morphine to 3-0Me in codeine 
reduces the potency but a maximal effect is still obtained. This is in contrast to some 
N-allyl series of thebaine derivatives in which 3-0Me compounds are agonists but their 
counterpart 3-0H oripavines are antagonists [Lewis, 1978]. 
Both the cyclic AMP and the ['sS]-GTPyS intracellular assays were used for testing 
several buprenorphine analogues including the two isomeric pairs: BU46 and BU47; 
and BU95 and BU96. All compounds showed partial agonist activity with similar 
efficacy in both assays. However, the potency of the compounds was different in the 
two assays being IO-fold lower in the cyclic AMP assay. This may be attributed to the 
different assay conditions. The cyclic AMP assays were performed in Krebs solution 
using whole cell preparations, but the ['sS]-GTPyS binding assays were conducted in 
cell membranes and in a non-physiological buffer containing HEPES, Mg++ and Na+. 
Indeed, lower ICso values have been obtained for cAMP assays conducted in whole 
cells than in cell membranes. For example DAMGO has an ICso 20nM in cell 
membranes and an ICso 90 nM in whole cell preparations [Sadee et aI., 1991; Lambert 
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et aI., 1993]. These data perhaps suggest a more efficient coupling in the 'artificial' 
membrane system. In addition, in binding assays, the occupancy curve for the opioid 
agonist DAMGO in Krebs solution is on the right side (approximately 2 log units) of 
that in the eSS]-GTPyS binding assay buffer, indicating that 11 opioid receptors are in a 
low agonist affinity state in Krebs solution, but in a higher agonist affinity state and 
therefore more tightly coupled to effectors in the eSS]-GTPyS binding assay buffer 
[Traynor & Nahorski, 1995]. 
The low efficacy profile of the buprenorphine analogues at 11 opioid receptors, as 
indicated by the lack of 11 agonism in the guinea-pig ileum, was confirmed by the 
eSS]-GTPyS binding and cAMP assays in SH-SY5Y cells. Although this cell line 
possesses a large population (approximately 200 fmoVmg protein) of Jl opioid 
receptors [Traynor & Nahorski, 1995], all compounds showed rather low efficacy, 
affording values between 31.6% - 53% of the maximum response seen with fentanyl, 
even at concentration of 10 JlM, thus indicating that all compounds were partial 
agonists at 11 receptors in this system. Indeed, all of the analogues had slightly lower 
efficacy than the parent compound buprenorphine which itself gave 70% of the 
response seen with the full agonist fentanyl. This explains why the ring constrained 
buprenorphine analogues show agonism via lC-receptors rather than Il-receptors in the 
guinea-pig ileum preparation. 
Replacement of N-CPM by N-Me (BU4) did give increased agonist activity with 
maximal response increasing from 40% to 100% of the fentanyl response. This is in 
agreement with the theory that a cyc\opropy\ group on the nitrogen atom of opiates 
confers antagonist activity [Casy & Parfit, 1986]. 
In spite of the observed low efficacy compared to fentanyl, all of the compounds were 
potent with ECso values of less than InM in the eSS]GTPyS binding assay. No 
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significant differences were seen between the ring constrained compounds in efficacy 
and potency suggesting the position of the tertiary OH is not crucial for Jl activity, 
though the compounds were less active than buprenorphine where free rotation about 
the C7-C19 bond is allowed. 
The results described above are consistent with a pattern of low efficacy at Jl 
receptors with high efficacy lC-agonism and 8-agonism. All the compounds were 
similar in potency and efficacy except for the isomers BU46 and BU47 which showed 
a IO-fold difference in potency at lC receptors in the guinea-pig ileum, and compound 
BU48 which was the most potent a-agonist examined. This information needs to be 
considered in relationship to the proposals for the interaction of the oripavines with 
opioid receptors. 
lC and Lt receptors 
The proposed model for receptor binding (Diagram 4.1) suggests the need for a Jl-
agonist binding site above the plane of the oripavine ring and for a lC-agonist binding 
site below the ring. The results which show that all compounds are lC agonists and 
possess low efficacy at Jl receptors, are in line with the structural features required of 
this model i.e. the additional alkyl ring in the buprenorphine analogues is fixed below 
the plane of the ring of the oripavine. 
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Diagram 4.2 The structure of BU47 showing the distances from the CwOH 
to the tertiary N atom, q-OH and C6-OMe; and angles between 
G9-0H to CWC? bond (alpha) and CW C20 bond (beta). 
Although in purely distance terms the 19-0H group is not in a dissimilar position in 
relation to other functional groups in the different molecules (Diagram 4.2) (Table 
4.2), the actual location in space is very different as shown by the torsion angles 
(Diagram 4.3). Thus for example the tertiary OH group in BU46 could bind to a 
suitably located hydrogen bond donor or acceptor which would not be available for 
the same OH in BU47 (Diagram 4.4). This is obviously important for potency 
presumably by interaction with a vital hydrogen binding site and resultant contribution 
to conformational changes in the 1( receptor as a ftrst step in the transduction of an 
agonist response. However, it makes little difference to the afftnity, probably due to 
contributions to the binding affinity from many other groups in the molecule or there 
may be a suitably placed hydrogen bonding site for BU47 in the receptor, but which 
cannot lead to the transduction of a response. 
These ideas would directly support the binding model of Hutchins and Rapoport 
[1984] with the presence of a hydrophilic site (Le. the hydrogen bonding site) 'above' 
the molecule and a lipophilic site 'below' the molecule. 
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OMe 
c 
C 
H 
HO H 
H 
D· m 4 3 Partial structure of BU47 (looking down the C20-C19 ~is) 
tagra . showing torsion angles between q 9-0H and C20 subSl1tuents. 
CB 
(I) 
~appa hydrophilic binding site CB , , loot" 
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Diagram 4.4 Partial Structure of BU46 (1) and BU47 (2) showing the H bond 
could form between the OH in BU46 and the kappa hydrophilic 
binding site but not the OH in BU47. The 19-0H in BU47 could form a 
H-bond with another site on the receptor which is not important for the 
transduction of an agonist response.Dotted lines indicate potential hydrogen 
bond. 
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The same arguement should apply to the isomeric pair BU95 and BU96 which 
contain two methyl substituents at C20 and therefore are highly substituted as in 
buprenorphine. However, this is not the case. Indeed the potency of BU95, where the 
OH is in the same position as the more active isomer BU46, was found to be 
equivalent to the potency of BU96 and both were similar to the potency of the 
weaker BU47. The changes are not due to differences induced in the molecule by the 
methyl group, since the position of the 19-0H group relevant to other atoms in BU46 
and BU95; and BU47and BU96 is very similar (Table 4.2). This suggests that the 
methyl groups in BU95 are interfering, either directly or indirectly by altering 
receptor fit, with the ability of the 19-0H in BU95 to bind to the receptor by H-
bonding (Diagram 4.5). Indeed the latter explanation would seem to be the case, since 
the methyl substituted derivertive BU96 has somewhat reduced affinity than the less 
substituted BU47. In both compounds the 19-0H is not in a position to interact with 
the hydrogen bonding site which is important for the K agonist potency of BU46. 
kappa hydrophilic binding site Cg H H,,7\ 
! ~C 
C19 ~ HI H 
kappa lipophilic binding site 
Diagram 4.5 Panial structure of BU95 showing possible interference 
of Go-methyls with receptor fit. 
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1) receptors 
Since all the buprenorphine analogues tested showed 0 agonist activity with similar 
binding affinity, it seems that the 8 agonist binding site is not differentiated by the 
compounds and may also, like the 1( site have a lipophilic region located below Cs . 
There was no difference in potency and efficacy between the isomeric pairs examined. 
However, the dimethyl substituent derivatives BU95 and BU96 (ICso 4.l±1.6 oM and 
7.2±O.2 nM respectively) possess slightly lower potency than the corresponding 
unsubstituted BU46 and BU47 ([Cso 1.310.3 nM and 3.610.3 oM respectively). It is 
therefore likely that the extra methyl groups again do not fit the 8 agonist binding site 
better than the H atoms. 
In contrast, BU48 has higher potency and efficacy at S receptors. This must be due to 
the 6-membered ring in this compound (Diagram 4.6), in contrast with the other 
compounds which have a 5-membered ring. This could relate to improved binding due 
to the extra C atom leading to a shift in the position of the 19·0H group in BU48 
which may be more favourable for combination via H-bonding to the 8 receptor 
(Diagram 4.6). i.e.the exact position of the OH in BU48 may be extremely critical. 
Alternatively it may be that the 6-membered ring itself i.e. its extra C atom, interacts in 
providing additional hydrophobic interaction which contribute to the observed effects. 
In contrast to the functional responses, binding assays for all compounds at /) receptors 
are similar, including compound BU48. This suggests the position of the OH, even in 
the highly active BU48 is not important for affinity, unlike its apparent role in efficacy. 
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OMe delta lipophilic binding site 
o 
I 
\/ 
/' delta hydrophilic binding site 
Diagram 4.6 Partial structure of BU48 showing H-bonding may increase 
delta intrinsic activity or the six membered ring itself contributes 
to agonist response. Dotted line indicates potential hydrogen bond. 
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Table 4.'2 The relative position of CwOR function to other groups in the different buprenorphine analogues 
Compound 
BU46 
BU47 
BU48 
BU95 
BU96 
BU61 
Distance CO A) between OH 
and 
N 3-0B 6-0Me 
6.743 8.475 3.204 
6.106 7.417 4.169 
6.275 7.992 3.151 
6.734 8.458 3.179 
6.216 7.545 2.858 
6.089 7.752 2.980 
Angle (0) between OH bond 
and 
C7-C9 bond Cw C20 bond 
111.48 112.53 
110.64 110.51 
114.34 108.68 
110.65 113.75 
109.66 112.32 
110.00 109.18 
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Torsion angle n between OH bond 
and 
Czo-OH (Me) bond Czo""OH (Me) bond 
-46.5 75.2 
-151.3 -30.0 
-179.6 -62.6 
-42.8 79.9 
-162.8 -40.7 
-170.7 -48.5 
Overview 
Buprenorphine has a distinct pharmacological profile. The aims of the present 
investigation were to determine the importance of the C7 substituent in the activity of 
buprenorphine (Figure 1. 8) with regard to affinity for opioid receptors and the ability 
to cause an agonist response. 
Obviously in buprenorphine the C7-C'9 bond can rotate freely and only limited 
information can be gained of the recognition site for the C7 substituents from studying 
this compound. However, the use of constrained analogues in which the spatial 
arrangement of atoms around C'9 are fixed as described in this thesis can enable us to 
leam about the topography of the ligand recognition site and features which are 
important for both ligand binding and signal transduction. 
The results obtained suggest that the 19-0H function in buprenorphine and analogues 
does not play an important role in differentiating ligand affinity for ~-, 0-. and K-opioid 
receptors. However this OH function may be more important in events related to 
agonist activation of the receptor, as determined by the ability to activate G-proteins in 
the cell assay or muscle contraction in the bioassay. 
The findings substantiate the view that ~ and K opioid binding sites differ in their 
interaction with the oripavine group of molecules, and show that Il-receptor 
interactions are more allied to K-receptor interactions. Indeed, the compounds all 
appear to be more efficacious at 8 and K receptors and only partial agonists at P-
receptors. 
The binding si te for the rigid alkaloids is believed to be in the transmembrane domains, 
indeed a conserved aspartic acid residue in the third transmembrane domain is believed 
to be important for the ionic interaction with the tertiary nitrogen function of these 
molecules [Uhl, et, aI., 19941. See figure(4.7) below and receptor diagram (4.8). 
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/ Eb Me NH - . + ----------- 0 -C _ Cl-fl -- Asp-
O~ 
Diagram 4.7 Possible tertiary nitrogen ......... Aspartic acid. 
Potential lipophilic sites to accomodate the alkyl substituents on buprenorphine and its 
analogues is presumably made up of amino-acids such as Phe, Leu, Val which are 
abundant in the hydtophobic a-helical regions of the receptor [Uhl et.a!., 1994]. 
Potential hydtogen bonding sites are also numerous. However, within the 
transmembranes domains likely amino-acid substituents with hydtogen bonding 
potential do vary between receptor types. Examples of potential H bonding 
substituents include serine, cysteine, aspartic acid, lysine. These occur in 
transmembrane domains but are generally conserved across the three receptor types 
and thus are unlikely to contribute to differences in the effects of the oripavines. Those 
residues that differ between receptors and could contribute to different H-bonding are 
highlighted in the receptor diagram (4.8). 
The approaches used in this thesis, together with modelling of the opioid receptor by 
groups such as Hruby, Mosberg, Akil and Portoghese allied to site-directed 
mutagenesis studies should lead to a much more informed approach to drug design. 
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tl..E. L V 1: S A R A E: L Q S E. - U - - - - - - - - - - - - - - - - - - Y....N. LSD A F e S A F P E. A " A N A E. G .s. PGA R 
tl..E.-~IQIFRG~PGPTCSPSACLLeNSS~FP----tlWAE:E.-----D.s.N"SV~EDQQLE 
MDS.s.TGPGNTS~C.s.DUAQASCS-12.APG~LNLSH~DGNQ.s.D12.CGLNRT"LGGND.s.LCPQ 
Transmembrane 1 Transmembrane 2 
( . ) ~(---------------------
~ - .s. L a L ILl A I TaL Y S A ~ A Y-ll.1. L l3...N V I, V M F G I V R Y T K L K TAT N I Y I f N L A LAD A L A T S 
~HI.s.paIPVI~VL.s.VYFVVGLVl3...NSLVMFVIIRYTKMKTATNIYIFNLaLADaLVIT 
TG.s.P.s.MVTAITIMALYSIVCVVGLF~FLVMYVIVRYTKMKTATNIYIFNLALADAIATS 
Transmembrane 3 
--------~) ( , 
T L £ F 0 S a K x...L....M E T W P f GEL L....C...E A ~ L SIP Y Y N M F T S 1fT L T M M S Y P B Y I A V C H P V K ALP f R 
IMPfOSAVx...L....MNSWPFGDVLCKIVISIDYYNMFTSIFTI,TMMSYDBYIAVCHPVKALPFR 
TLPfOSVN~GTWPFGTILCKIV1SIDYYNMFTSIFTLCTMSVpBYIAYCHPVKALPFR 
.,. 
Transmembrane 4 
( ) .... ,---------
L£A~LINICIWV~G~V12.IMVMAVIQPRDGA--VVCMLOFPS12.--SWYWPTVT~ 
ti L K A K I I N I C I W L lw'L.S. S ~ I S A I'LL G G II v RED V D V I E C S L 0 F P D D E Y ~ - W D L FM K...LC. 
L£RN~VNVCNtllkS.s.AI"L£VMF~TLKYBQGS--~DCT~TrSH£--T~ENLL~ 
Transmembrane 5 Transmembrane 6 
-----------------~~ ~(--------------
'LE L F a F v v P I L I I T V C Y G L M L .kJL.L R S V R L L S G S K E K D R S L R R I T R M V 1, V V V G A .E v OLC..JY. A E 
'LE v F A f v I e v k..Ll I :u::...x T L M I 1, B L K S V R L L S G S B E K D RN L R R I T K L Y L V ~ V A V F I I C W T P 
'LE I LlU: I M P I L I I T V C Y G L M I I, B L K S V B M L S G S K E K D R N L R R I T R M V L V V V a v f I V C W T P 
Transmembrane 7 
________ --'0:::....." ( )( 0 , 
IHIFVIVWTLVDINRRDPLVVAALtlLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRTP 
I H I f I L Y. E U G S ISH S I A - A L S .s. Y Y F C I A L G Y T N S S L N P V L Y A F L PEN F K R C f R D L.C. F £ I 
LJLl. Y llJ I K l'.....L I T ~ - P E I T F Q T v.s. W H F C 1 A L G Y T N S C L N P V L Y A F L PEN f K R C F R E L.C. T £ T 
CGBQEPG.s.LRBP~AIT~RVTACTPSP---------"PGGGAAA 
KMBMER~TNRY$N-IVQDPAE.-----------MRDVGGMNK12.V 
SSTIEQQNSTRVRQNI-a£HP.s.TANTVDRTNHQLENLEAETAeLP 
Diagram 4.8 Sequence alignment of opioid receptors. i conserved aspartic acid 
residue in tntnsmembrane Ill. 0 Potential H bonding sites found in 1( and 
15 but not ~ receptors. x Potential H bonding sites found in 1( receptor. 
a Potential H bonding sites found in 15 receptoT. 
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41 15 
50 K 
59 I.l 
100 15 
110 K 
119 I.l 
160 <5 
170 K 
179 J.! 
216 0 
229 K 
235 I.l 
276 5 
289 K 
295 I.l 
336 15 
348 K 
354 I.l 
372 15 
380 K 
398 I.l 
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